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secretaries who entered data from extensive
forms filled in by the patient. They have filled
out forms endorsing: dizziness, low back pain,
blurred vision, headaches, gastritis, rashes,
and a host of other symptoms, entirely irrel-
evant to why the patient saw the doctor.
Sometimes I can’t even figure out why the
patient saw that doctor, what the doctor
found or what happened at the visit. Com-
pleteness to the point of irrelevancy.
I can’t seriously say that computerized
records are bad. Overall they probably are
good. In the hospital charts are never lost.
Lab values are always available. Doctors’ notes
are always legible. There is less chance for
errors. Alerts on labs or drug interactions can
be made automatic to lessen their chances
of being overlooked. But they are not an un-
alloyed good. They undoubtedly save money,
especially if notes are no longer dictated.
Dictated notes can, of course, be computer-
ized, but there is a tendency to try to make
everything as click-driven as possible.
In the future, when all records are
computer based, hopefully simplified and
universal in nature, the payoff, in which all
patients can carry the important parts of
their records on a computer chip embed-
ded in a medical record plastic card, will
be worth it. Until we get there, electronic
records are, in my mind, a mixed blessing.
They represent the “regression toward the
mean,” a method which reduces the qual-
ity of the best, improving to some degree
the quality of the worst, but primarily mak-
ing all notes mediocre but more readily
available and, perhaps most importantly,
readily available to those who really count
in our medical world, the insurance com-
panies, the ones who pay the bills.
In the United States, where some elected
officials view George Orwell’s 1984 as a tem-
plate rather than a nightmare, the concept of
a national repository of medical information
poses a great threat to our privacy.
– JOSEPH H. FRIEDMAN, MD
Disclosure of Financial Interests
Joseph Friedman, MD, Consultant:
Acadia Pharmacy, Ovation, Transoral; Grant
Research Support: Cephalon, Teva, Novartis,
Boehringer-Ingelheim, Sepracor, Glaxo; Speak-
ers’ Bureau: Astra Zeneca, Teva, Novartis,
Boehringer-Ingelheim, GlaxoAcadia, Sepracor,
Glaxo Smith Kline, Neurogen, and EMD
Serono.
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Commentaries
Almost every op-ed piece on medical care
in America praises electronic medical
records. They are never lost. They can be
sent to any office in the world in a split sec-
ond. The records can be faxed, often di-
rectly from the computer. The patient can
get a copy of the record in a flash. The doc-
tor can field questions from the patient or
another doctor with the virtual chart avail-
able for review in a few seconds. Some charts
may be accessed from sites distant from the
office so on-call doctors can renew medi-
cines and answer queries even when they
don’t know the patient. Sounds great, and
to some extent it is. But have you visited a
doctor who uses computer records?
My primary care provider (PCP) uses
the computer to enter data, and now, so do
I. The first obvious drawback is that it re-
quires the doctor to appear rude. As the
patient speaks I have to enter information
via the keyboard. For a new patient I have
go through a vast array of alphabetized
possible illnesses to click on whatever disor-
der they may have had to complete the
medical history. When the illness is not on
the list, entering it takes more effort. It is a
time consuming and annoying process.
When my own PCP started using the
computer, he now longer faced me as we
talked. Half his concentration was on the
keyboard, half on me. Previously we’d chat
and he’d casually make entries in the chart,
by hand. Since “if it isn’t charted it didn’t
happen,” he’s entering everything as quickly
as possible.
I tolerate my own misspellings because
I don’t have the time or patience to review
what I’ve written. If the patient remembers
something relevant to a preceding topic I
have to backtrack and enter that bit of data.
It has a subtle influence to reduce pursuit
of further information. Worse still, because
it takes longer than a handwritten note,
there is now even less time for a visit than
there used to be. And it is truly amazing
how many of my patients say, “Oh, by the
way…” presenting me with a major prob-
lem to discuss, after I’ve closed the program.
When I want to review the last visit, I
have to close down my current screen and
flip up the previous one. I can minimize the
current screen but it’s not like turning pages.
Then I go back to the current visit; but if I
need to check another fact about the previ-
ous visit, I have to minimize or save the cur-
rent note and recheck the old one. It’s not
nearly as efficient as flipping through the chart.
When I want to check a lab, or an MRI, I
have to close the current note and hunt for
the data, read it, close the screen, open the
new note, and hope that I can remember ex-
actly what I want to include in the current
note. Sounds challenging? Not really, but
quite annoying. And the software program
that I use doesn’t accept outside lab or imag-
ing reports so that the labs are entered in a
different software program. I have to not only
minimize my current note, but I have to open
a whole new program, find the patient and
then the data set that I need.  It’s like com-
parison shopping on the internet, first check-
ing a price at one site then at another, except
in the office there are major time constraints.
There’s no doubt that I don’t have to
worry about losing charts, that is, unless the
receptionist mistypes the patient’s name. In
the old days, the charts were kept alphabeti-
cally, so the chart on “Bailey” misspelled as
“Baily” was easily found, whereas the computer
generates the list of everyone named Bailey,
but Baily won’t appear. Now that I’ve had this
problem a few times, I’ve learned to reduce
the number of letters I use, so that “Bail” will
include all names beginning with those four
letters. If I can’t find “bailey” then I try Bail, or
Bal. If there are a lot of names beginning with
those letters, I’m in trouble. An entry of “Boley”
may remain unknown forever.
My chart notes have taken a nose dive in
quality. I used to dictate my notes and prided
myself on their completeness. No longer. Now
the history contains a bunch of click items,
“patient admits history of hypertension, val-
vular disease, GERD and eye problems.” The
click method is important for billing.
I get electronic notes from other doc-
tors that seem to have been generated by
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The Decline and Fall of the Red Tomato

premature infants, and those with temporary or enduring im-
mune deficiencies such as those suffering from HIV infections
or those undergoing extensive radiation therapy.
The germs causing salmonella food-poisoning, historically,
have clustered in the intestinal tracts of domesticated chickens;
accordingly, the great majority of salmonella food-poisoning
cases occur in those eating raw or undercooked eggs. These
bacteria often contaminate the interior of the egg prior to its
being encased by the shell; and therefore sterilizing the chicken-
shell may not affect the integrity of the Salmonella bacteria
harbored within the egg. Adequate cooking of eggs, then, re-
mains the most dependable means of preventing Salmonella
food-poisoning.
More recent epidemiological studies of recent cases of Sal-
monella food poisoning now cast doubt that tomatoes were
the sole, or even principal, source of the outbreak.  Given the
complexities of  farming, storage, distribution and retailing of
a vegetable such as the tomato, the actual point of intimate
contact between the pathogen and the vegetable carrier may
never be determined to anyone’s critical satisfaction.
From whence came the tomato? It is one of many New
World contributions to the cuisines of Europe, Africa and Asia.
Some think that it originated in the highlands of Peru; but
most agronomists now believe that its deliberate cultivation was
begun by Central American Aztecs. Indeed, the Aztec word
for the vegetable is xitomatl.
Cortez conquered the city of Tenochtitlan in 1521 and
the tomato plant soon found its way east across the Atlantic,
first as an ornamental plant.  By 1544 tomatoes entered into
the southern Italian cuisine, called pomi d’oro [golden apples].
The transplanted tomatoes of the 16th Century are now pre-
sumed to have been the yellow cultivar, hence the name
“golden.”
In France the tomato was called pomme d’amour  or love
apples because of tomato’s alleged aphrodisiac quality. In En-
gland as well as the northern nations of Europe, however, the
tomato was viewed as a poisonous plant [perhaps anticipating
the science-fiction cinematic thriller of the 1960s, “Attack of
the Killer Tomatoes.”] Not until the 19th Century were toma-
toes incorporated in the general diet of Germanic and English-
speaking nations.
The average American, through his diet of pizza, salsa, tortillas,
tomato soup, garden salads, ketchup and sundry other culinary ex-
ploitations of the tomato, now happily consumes over 38 pounds of
tomato per year.
– STANLEY M. ARONSON, MD
Disclosure of Financial Interests
Stanley M. Aronson, MD, has no financial interests to
disclose.
CORRESPONDENCE
e-mail: SMAMD@cox.net
 “Do you really want to purchase these tomatoes?”, whispered
the checkout woman at the supermarket.  She stared at the
tomatoes for a moment as though they were packets of lethal
anthrax and then exclaimed, “Last week it was poisoned toma-
toes; a month ago, contaminated eggs;  and don’t forget such
things as avian flu and that sickness from the Nile River. Life is
getting scarier.”
I dutifully paid for my groceries, including the lush toma-
toes, tacitly agreed with the employee about the sundry haz-
ards of urban existence and reflected upon her litany of fo-
cused fears. To what extent were her anxieties justified? To what
degree were they part of a nonspecific [and possibly counter-
productive] cloud of fear that so many experience in a world of
expanding complexity?
On June 7, 2008, the US Food & Drug Administration
(FDA) warned American consumers that an outbreak of Sal-
monella infection “had been linked to consumption of some
raw red plum, red Roma, round red tomatoes and products
containing these raw tomatoes.”  By early summer of 2008,
the FDA had substantiated 887 cases of salmonella enteritis,
inferentially associated with the consumption of certain variet-
ies of tomato. The outbreak centered particularly in Texas and
New Mexico. [Salmonella enteritis, it should be pointed out, is
not that rare a clinical phenomenon. In an average year, the
United States witnesses about 1.4 million cases. Still, the gov-
ernment publicized this outbreak since they thought that its
source was readily identified.]
What is salmonella? It is the name given to a genus of bio-
logically related bacteria [some innocuous, some dangerous]
that inhabit the gastrointestinal tracts of domesticated birds
and animals as well as certain reptiles such as turtles.
Two American scientists, Theobald Smith [1859 – 1934,]
a physician and experimental pathologist, and Daniel Elmer
Salmon [1850 – 1914], a veterinarian who had founded the
governmental Bureau of Animal Industry, a precursor to the
FDA, were jointly studying the causes of a sometimes lethal
cholera-like disease in domesticated swine. In 1885 they iso-
lated a specific bacterium which was later named Salmonella.
Since then, other members of the Salmonella genus have been
shown to cause typhoid fever, paratyphoid fever; and one spe-
cies of Salmonella, Salmonella enteriditis, is the major cause of
food poisoning in this nation and abroad. The interpersonal
relationship between Salmon and Smith is both odd and con-
tradictory. On the one hand, their collaborative investigations
yielded much scientific insight into the nature of enteric infec-
tion and the development of antibodies to these illnesses; on
the other hand, there was much continuing enmity, even out-
right antagonism, between the two.
Salmonella food poisoning [enteritis] causes an acute ill-
ness characterized by an incubational interval of 12 to 18 hours,
moderate fever, abdominal distress, diarrhea [usually non-
bloody] and in most cases recovery within four or five days.
The self-limiting illness tends to be more serious in three cat-
egories of vulnerable humans: the nursing home elderly, the
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Physician and patient attitudes toward pain treatment have
fluctuated dramatically in recent years, influenced by oppos-
ing concerns regarding humanitarian considerations and the
potential abuse of our most effective analgesic class, the opio-
ids.  Unfortunately, the widespread abuse of opioid prepara-
tions, with its social consequences, led to today’s close govern-
ment restriction.1 Admittedly, opioid medications, both illicit
and prescribed, are abused, but when prescribed for appro-
priate medical indications, the medications can improve our
patients’ physical and emotional well-being.2 Fortunately, many
barriers to pain treatment have diminished over the past 20
years. In addition, we have more effective delivery systems and
dose forms. Consequently, we have witnessed a dramatic in-
crease in opioid prescribing for all forms of pain, including
acute, cancer, and other persistent pain conditions.2,3 This
greater willingness to treat pain has been marked by an in-
crease in opioid production and distribution by the pharma-
ceutical industry, which has embraced pain treatment as a
growth market.4 While all government agencies and healthcare
experts regard appropriate pain treatment as good medical
practice, many question whether the pendulum has swung a
bit too far in favor of liberal or even excessive opioid prescrib-
ing by some practitioners.  Despite this notable escalation in
opioid prescribing and consumption throughout the US, in-
adequate pain treatment and inequalities in patient treatment
persist.5,6
Coinciding with the greater availability of prescription
opioids, there has been a parallel increase in the abuse of pre-
scription opioids, and in  overdose deaths throughout the US.7
Substance abuse involving heroin and stimulants, while wide-
spread, generally is associated with major metropolitan areas.
Over the past ten years, there has been a marked  upsurge in
accidental overdose deaths and emergency unit admissions in-
volving prescription opioid overdose in previously less affected
rural communities in states such as Maine, West Virginia and
Vermont. (Table 1)  In many of these communities, illicit opio-
ids had been much less available, but with the dramatic in-
crease in opioid prescribing for pain, many prescription opio-
ids are being diverted for illicit consumption.7,8 According to
the most recent DEA data, hydrocodone, oxycodone, and
methadone are the predominant opioids contributing to acci-
dental opioid overdose deaths, exceeding those reported for
heroin and cocaine.  Several factors have contributed to this
escalation in prescription drug abuse; e.g., greater availability
of high-dose sustained release opioid formulations, the purity
and perceived safety of prescription medication, and the ease
of access to these medications from their parents’ medicine cabi-
net by college age adults.  The majority of opioid-related deaths
involve multiple central nervous system depressants, including
alcohol and benzodiazepines, in addition to stimulants such as
methamphetamine, and cocaine.8 Hydrocodone appears to be
the predominant opioid associated with prescription opioid
abuse, probably reflecting its’ greater availability as the most
Opioid Therapy and Prescription Drug Diversion
Frederick W. Burgess, MD, PhD, and Jayne Pawasauskas, Pharm D, BCPS

prescribed opioid.  Oxycodone follows as a close second, with
methadone a more distant third.7 However, in considering ac-
cidental overdose deaths, methadone has proven much more
lethal, despite the fact that it is prescribed an order of magni-
tude less than oxycodone and hydrocodone, reflecting
methadone’s unique pharmacology, which will be discussed in
a subsequent article in this issue.   Methadone is commonly
sought by opioid addicts as a means to stave off withdrawal
symptoms between episodes of abuse or dismissal from an opioid
treatment facility, fostering a surprisingly high street-value.9
It is impossible to completely separate the analgesic properties
and the abuse liability of the opioid drugs.  Efforts are underway to
devise better opioid delivery systems and dose forms to reduce the
ability of abusers to tamper with prescribed medication.  Currently
available sustained release opioid preparations contain large, even
toxic quantities of medication that may be released rapidly when
used inappropriately.  Sustained release morphine and oxycodone
can become immediate release preparations if crushed, chewed, or
combined with alcohol, via concomitant ingestion or physically ex-
tracted.  Snorting or injecting the extracted components can pro-
vide a “high” similar to heroin.  Transdermal fentanyl patches con-
tain a gel that may be ingested transbuccally or injected, and even
discarded used patches still contain a substantial quantity of active
ingredient, making safe disposal an important consideration.10 Sev-
eral manufacturers are developing new delivery systems, such as in-
cluding an encapsulated pellet of the opioid antagonist naltrexone,
which would be activated by tampering with the tablet and block
the effects of the opioid medication, possibly even inducing with-
drawal in the opioid tolerant individual.  Other formulation modi-
fications include a tablet that turns into a hard solid mass if tam-
pered with.  While these modifications will reduce the abuse poten-
tial of many sustained release products, they will not totally elimi-
nate the problem. Opportunity and availability remain important
contributors to substance abuse.
Finding ways to minimize prescription drug diversion,
particularly when prescribing potent and/or large amounts
of opioid for cancer pain or other persistent pain conditions,
is an essential social and legal responsibility for the prescrib-
ing physician, patient, and their caregivers.  A variety of strat-
egies have been proposed to detect and reduce diversion.
Some measures are controversial, such as routine urinary drug
testing (UDT) of the patient to detect substance abuse and
to determine if the patient is indeed taking the prescribed
medication rather than selling it.  UDT is regarded by many
physicians and patients as a sign of mistrust and a violation of
their privacy. (see article by Telliogolu)  Other measures are
practical and simply reflect evidence of a good medical prac-
tice.  Simple examples of good prescribing practices include
the following guidelines.  When starting a patient on a new
opioid, begin with a small quantity of medication.  Should
the patient experience side effects or not tolerate the pre-
scribed agent, it will save on cost and reduce the amount of
unused medication that has the potential to be diverted.  It is
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not infrequent that a patient will not
respond well to one or more opioids,
and the unused portions cannot be re-
turned to the pharmacy and should not
be accepted by the physician, making it
difficult to ascertain proper disposal.
(Table 2).  Patients should be advised
about the potential risks of opioid di-
version by family, friends, and other
caregivers.  They may contact the De-
partment of Health to insure proper
disposal of unused medication, and
should be urged not to leave the unused
supply sitting on the counter or in their
medicine chest.  It is advisable to include
the direction “lock this medication up”
directly on the prescription to document
that the instructions were clearly deliv-
ered to the patient.   Surveys of college
students consistently show that 60-70%
gain access to prescription opioids from
medications prescribed to family mem-
bers and friends.12 It may also help to
write “Pharmacist to consult on medi-
cation safety” on each prescription to
reinforce the dangers of mixing medi-
cations and the need for security in stor-
ing the medication.  Risk of serious ad-
verse events increase with the number
of different medications taken.  While
patients are encouraged to use only one
pharmacy, they often get certain medi-
cations less expensively from different
sources, including mail-order suppliers.
In addition, patients with chronic pain
often have co-morbid problems of de-
pression/anxiety, and sleep disorders.
These patients are likely to have more
prescription needs and are probably
more likely to be doctor and pharmacy
shopping.  Drug-related fatalities usu-
ally involve the ingestion of several pre-
scription CNS depressants, often in ad-
dition to alcohol.  Every patient must be
warned about the serious risks of con-
suming alcohol with opioid prescription
medications.
Physicians prescribing opioids must
carefully document the dates and
amounts prescribed.  Good record-keep-
ing is essential to ascertain that the proper
amount of medication is being consumed.
This is particularly true for patients ob-
taining a 3-month supply of a controlled
substance from a mail order supplier.
Further, strongly advise the patient to
have prescriptions filled at only one phar-
macy to aide in monitoring the pattern
of use. In dealing with high-risk individu-
als, it helps to establish open lines of com-
munication with the pharmacist to aide
in identifying other physicians providing
opioid analgesics for these patients.  An-
other simple guideline is to emphasize
that only one physician should prescribe
opioid medication.  Patients seeking opio-
ids from multiple sources should be re-
garded as high risk for substance abuse.
Doctor shopping patients are often diffi-
cult to detect, and with HIPPA regula-
tions, it has become increasingly difficult
to share healthcare information.  Gov-
ernment efforts to monitor controlled
substance prescribing have typically been
met with skepticism.  While central moni-
toring can improve the detection of
medication abusers, it tends to have a
negative impact on physician prescribing
practices.  Rhode Island has an electronic
controlled substances monitoring system
which captures data on controlled sub-
stances prescribed within the state.  At
present, there is no direct feedback to
providers to assist in guiding prescribing
practices; however, to monitor high-risk
patients, the physician can gain access to
patient data by contacting the RI Depart-
ment of Health.  This system will not cap-
ture prescriptions filled across state bor-
ders or via mail order/internet pharma-
cies. Thus, vigilance, ongoing assessment,
and intelligent prescribing practices are
crucial to successful pain treatment and
to avoid drug diversion.
Gourlay and associates have pro-
posed “Universal Precautions” for pain
medicine prescribing.13 This approach is
based upon 10 principles focusing on
careful assessment, continued monitor-
ing, and reevaluation.
1. Make a careful diagnosis of the
pain source.  Assess co-morbid
conditions, such as depression, and
include them in the treatment
plan.  Psychiatric and substance
abuse disorders must be addressed.
2. Assess the risk of substance abuse, in-
cluding family history, current envi-
ronment, and personal history of sub-
stance abuse.  Urine drug testing may
be considered, with appropriate coun-
seling of the patient regarding illicit
drug use.  Some experts advocate
screening everyone as part of a ran-
dom process, others restrict it to prob-
lematic patients.  Not infrequently,
some individuals are found not to have
detectable levels of the prescribed
opioid, suggesting the possibility of
diversion. However, no action should
be taken on a single aberrant test.  Pa-
tient counseling and continued moni-
toring should be performed.
3. Obtain informed consent.  Long-
term opioid therapy for chronic pain
carries the potential for withdrawal,
and may be contentious.  In addition,
the consequences of opioid therapy,
including constipation, reduced tes-
tosterone levels, fatigue, etc…,
should be disclosed.  A sample con-
sent/agreement from may be found
at: http://www.painmed.org/pdf/
opioid_consent_form.pdf
Table 1. Estimated Mentions of Selected Opioid Analgesics: 1997 – 2002 , as Reported in DAWN
Year Meperidine Morphine Hydromorphone Oxycodone Hydrocodone Codeine Methadone
1997 864 1,300 604 5,012 11,570 7,869 3,832
1998 730 1,955 937 5,211 13,611 6,620 4,810
1999 882 2,217 1,313 6,429 15,252 4,974 5,426
2000 1,085 2,483 1,983 10,825 20,098 5,295 7,819
2001 665 3,403 2,003 18,409 21,567 3,720 10,725
2002 722 2,775 2,667 22,397 25,197 4,961 11,709
Values are expressed in number of estimated mentions.  ED visits includes dependence, drugs taken for psychic effects
or suicide attempts.  Source: Office of Applied Studies, SAMHSA, DAWN, 2003.
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4. A signed treatment agreement is
recommended defining the obli-
gations of the physician and pa-
tient is helpful in defining the pa-
rameters to guide the continuation
of opioid therapy and for discon-
tinuation.  This avoids arguments
and misunderstandings.
5. Document pain levels prior to and
after the initiation of opioid
therapy.  It is essential to document
an effective analgesic response to
warrant continued treatment.
Pain scales are not always the best
measure, but other functional im-
provements may be useful in as-
sessing the treatment response.
6. Initiate an appropriate trial of
medication, including opioids and
adjuvant analgesics.
7. Frequently reevaluate measures of
efficacy.  Seeking corroboration
from family members and signifi-
cant others can help to provide a
better picture of treatment suc-
cess, or of failure.
8. Regularly assess the 4 A’s of pain
treatment: analgesia, activity, adverse
effects, and aberrant behavior.
9. Periodically reevaluate the
patient’s underlying condition and
any co-morbid conditions.
10. Documentation!  The physician
and patient’s best protection from
legal entanglement is careful docu-
mentation of the treatment plan
and monitoring efforts.
Opioid analgesics should not be con-
fused with quality pain treatment!   Opioid
medications remain one of our most effec-
tive treatments for pain, but they are not the
best and only solution for every patient.
Cognitive/behavioral therapy, supervised
exercise programs, interventional pain treat-
ments, and nonopioid analgesic medications
should be incorporated into an individual-
ized treatment program.  When appropri-
ate, an opioid medication trial is a reason-
able consideration.  When dealing with per-
sistent pain, both the patient and physician
should have realistic expectations and goals.
Clinical pain trials consistently demonstrate
that opioid treatment can improve the
patient’s pain and global sense of well-be-
ing.  That being said, few patients will be-
come pain free, and most will continue to
report elevated pain scores, despite aggres-
sive opioid administration.  Long-term opioid
therapy should be guided to reduce suffer-
ing, improve quality of life, but not with the
expectation of completely eliminating pain
sensation.  Guiding the patient’s expectations
in this area is essential.
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Table 2. Office of Drug Control Policy: New Guidelines for
Prescription Medication Disposal
• Take unused, unneeded, or expired prescription drugs out of their
original containers
• Mix the prescription drugs with an undesirable substance, like used
coffee grounds or kitty litter, and put them in impermeable, non-descript
containers, such as empty cans or sealable bags, further ensuring that
the drugs are not diverted or accidentally ingested by children or pets
• Throw these containers in the trash
• Flush prescription drugs down the toilet only if the accompanying
patient information specifically instructs it is safe to do so
• Return unused, unneeded, or expired prescription drugs to pharmaceu-
tical take-back locations that allow the public to bring unused drugs to a
central location for safe disposal
The FDA advises that the following drugs be flushed down the toilet instead of
thrown in the trash:
Actiq (fentanyl citrate)
Daytrana Transdermal Patch (methylphenidate)
Duragesic Transdermal System (fentanyl)
OxyContin Tablets (oxycodone)
Avinza Capsules (morphine sulfate)
Baraclude Tablets (entecavir)
Reyataz Capsules (atazanavir sulfate)
Tequin Tablets (gatifloxacin)
Zerit for Oral Solution (stavudine)
Meperidine HCl Tablets
Percocet (Oxycodone and Acetaminophen)
Xyrem (Sodium Oxybate)
Fentora (fentanyl buccal tablet)
http://www.whitehousedrugpolicy.gov/drugfact/factsht/proper_disposal.html
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During the past decade the prescription
of long-acting opioids to treat a variety
of persistent pain conditions in the
United States has increased.1.2  Nation-
ally, the Centers for Disease Control and
Prevention (CDC) tracks a parallel rise
in accidental deaths related to prescrip-
tion opioids during this period.3  Based
on medical examiner data, states partici-
pating in the Drug Abuse Warning Net-
work (DAWN) report that the number
of unintentional deaths involving pre-
scription opioid analgesics has surpassed
those due to illicit drugs.4   With in-
creased availability comes the heightened
risk that prescription drugs will be acci-
dentally ingested, misused, abused or di-
verted.  Prescribing physicians have the
opportunity to respond to this threat
with preventive measures including edu-
cation and prescribing naloxone to any
patients who receive long-acting opioids.
Naloxone hydrochloride is an opioid
antagonist routinely used by emergency
medical personnel to rapidly and safely
reverse opioid-induced respiratory de-
pression.  It has also been prescribed di-
rectly to individuals at risk of an opioid
overdose, through naloxone prescription
and distribution programs.  Participants
in naloxone prescription and distribution
programs are trained in overdose preven-
tion, identification and response, includ-
ing calling 911, rescue breathing and
naloxone administration.  Naloxone is an
inexpensive, non-scheduled prescription
drug with no agonist properties or po-
tential for abuse.5-7  Administered to
someone using opioids, naloxone may
induce acute withdrawal, including
symptoms of nausea, vomiting, distress,
diarrhea, pain and agitation and less fre-
quently pulmonary edema.  Those symp-
toms are preferable to accidental over-
dose death. However, when someone is
near death due to underlying terminal
illness there may be circumstances in
which the medication should not be
used.   For many individuals prescribed
long acting opioids and for family mem-
bers who may accidently or inappropri-
ately access these medications, quick ac-
cess to naloxone is a safe option, and may
be a critical step towards reducing unin-
tentional opioid overdose deaths.  Across
the country, naloxone has been pre-
scribed and distributed to illicit injection
drug users, who have successfully admin-
istered to their peers with low rates of
reported complications.8-14  (Table 1) The
positive outcomes from community-
based naloxone prescription and distri-
bution programs encourage medical pro-
fessionals to learn from the example of
harm reduction programs and to reduce
accidental overdose by following nalox-
one prescription protocols for patients
receiving high dose opioids.
Targeted outreach to illicit opioid
users for overdose prevention misses a
large section of the population who may
also be at risk for an accidental opioid
overdose.   Recipients of prescription
opioids are at risk to misuse or abuse these
medications, and may benefit from take-
home prescription naloxone.  Hospitals,
medical clinics and physicians’ offices
provide an ideal contact for many indi-
viduals who should have access to this
potentially life-saving resource.  We rec-
ommend that doctors prescribing opio-
ids for pain management consider pre-
scribing naloxone and inform their cli-
ents of its proper use in the event of an
accidental overdose.  As is the case in ex-
isting programs, basic information must
be conveyed to patients who are receiv-
ing prescription naloxone. (Table 2).
Standard practice calls for potential
risks or side effects to be explained when
a new medication is prescribed.  None-
theless, the patient may not fully under-
stand this information.  The process of
prescribing naloxone provides a teaching
opportunity to emphasize the potential
risks of prescription opioids.  An addi-
tional benefit may be the reduced risk of
overdose with the extra information given
to patients.
Practical implementation of nalox-
one prescription would require that in-
dividuals receiving the prescription, or
their caretakers, be trained in its use and
given written instructions that someone
else could follow in the event of an emer-
gency.  Emergency naloxone prescribed
for home use is analogous to the com-
mon prescription of epinephrine (Epi
Pen) for anaphylaxis, rectal valium
(Diastat) for seizures, and glucagon for
hypoglycemia.  These medications are
prescribed to individuals with written
instructions that a friend or family mem-
ber may need to follow.
Project Lazarus15 in Wilkes County,
North Carolina, provides a model for the
widespread prescription and distribution
of naloxone in physicians’ offices, hospi-
tals, pharmacies, detox clinics, prisons
and emergency rooms, to patients at risk
Overdose Prevention: Naloxone with Long Acting Opioids
Sarah Bowman, Michelle McKenzie, MPH, and Josiah Rich, MD, MPH
Table 1. Large and Established Naloxone Prescription and
Distribution Programs in the United States (February 2006)
Year of Number of Number of reported
City/State establishment  trainings/prescriptions  overdose reversals
Chicago 1999 4,600 416
New Mexico 2001 1,312 222
San Francisco 2003 650 141
Baltimore 2004 951 131
New York City 2005 938 73
Sporer KA, Kral,   Annals Emerg Med 2007; 49: 172-7.
Table 2. Overdose prevention
education should include:
1. Signs and symptoms of an opioid
overdose.
2. Calling 911
3. Recommendation to consider fur-
ther training in rescue breathing
or CPR
4. Instructions for safe Naloxone
administration and storage
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for opioid poisoning.  Throughout Wilkes
County, providers will prescribe intrana-
sal naloxone to patients who fit within 14
subpopulations identified as potentially
benefiting from prescription naloxone;
e.g., patients at risk for taking prescrip-
tion opioids incorrectly as well as non-
medical opioid users. (Table 3)
Non-medical opioid use refers to the
recreational use of illicit or prescription
opioids including the use of a prescribed
opioid by someone other than the patient.
Project Lazarus, a component of the
region’s Chronic Pain Initiative, is the first
widespread prescription naloxone pro-
gram in the United States; this
groundbreaking project sets a new stan-
dard of care for pain management.
Naloxone is available for both intra-
muscular and intranasal administration.
In both forms it has been successfully
administered for peer reversal of an
opioid overdose.  Intranasal naloxone is
used by emergency departments
throughout the country, and is distrib-
uted through the overdose prevention
programs in Massachusetts, New Mexico
and now Project Lazarus in North Caro-
lina.  Although intranasal naloxone has
not been studied as thoroughly as intra-
muscular, life-saving results point to its
success. (Chart 4).  Researchers have
found limited data supporting the use of
intranasal naloxone prescribed for patient
use,16 yet field experience in Massachu-
setts and New Mexico indicates that this
option provides a viable alternative for
practitioners who are hesitant to distrib-
ute or prescribe needles for their patients.
Extensive experience with the pre-
scription and distribution of naloxone to
patients receiving high dose opioids is not
available; nonetheless, data from overdose
prevention programs targeting injection
drug users document the life-saving po-
tential of naloxone administered by
friends and family.  Further evaluation
of naloxone to prevent overdose in pa-
tients receiving long acting opioids needs
to be done.  Findings from Project
Lazarus will contribute to this process.
Expansion of pain management guide-
lines to establish specifications for edu-
cation about overdose prevention includ-
ing the prescription of naloxone will in-
crease access to changing standards of
care.  At this time, there is sufficient evi-
dence to promote patient education
around overdose prevention including
the use of prescription naloxone, as well
as including naloxone prescription into
pain management guidelines.
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Table 3. Potential Indication/Patient Population
(a partial list, those pertaining to prescription pain management)
High dose opioid prescription (>100 mg of morphine equivalence/day)
Any methadone prescription to opioid naive patient
Any opioid prescription concurrent with:
        smoking/COPD/emphysema or other
        respiratory illness or blockage
        renal dysfunction or hepatic disease
        known or suspected concurrent alcohol use
        concurrent benzodiazepine use
        concurrent SSRI or TCA anti-depressant
        prescription
Table 4. The First Nasal Naloxone Prescription Programs in
the United States (July 2007)
Year of Number of trainings/ Number of reported
City establishment prescriptions overdose reversals
Boston, MA 2006 283 48
Albuquerque, NM August, 2007 NA NA
Cambridge, MA August, 2007 NA 1
Personal communication with Maya Doe-Simpkins 8/31/2007, Bernard Lieving 8/31/2007,
and Louise Rice 9/11/2007.
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Methadone Analgesia for Persistent Pain:
Safety and Toxicity Considerations
Frederick W. Burgess, MD, PhD, and Jayne Pawasauskas, Pharm D, BCPS

Methadone, a synthetic mu-opioid agonist
with a uniquely prolonged and variable
elimination half-life, was developed in
Germany during the Second World War.
However, not until Dole and Nyswander
introduced the concept of using metha-
done as a treatment for heroin addiction
in 1965 did methadone gain a role in
clinical practice.1 Due in part to its asso-
ciation with drug addiction, methadone
found little application as an analgesic in
routine medical practice.  Even today,
many patients, fearing the label of “ drug
addict”,  are reluctant to accept a pre-
scription for methadone.  Furthermore,
many physicians mistakenly believe that
they cannot prescribe methadone for
pain without a special DEA license to
treat addiction.  Despite these barriers,
methadone prescribing for chronic and
cancer pain has been showing a gradual
increase.2,3  Efforts to promote greater use
of opioid analgesics for cancer pain treat-
ment spawned the development of sus-
tained release morphine and oxycodone.
The ability to deliver continuous opioid
blood levels greatly improved the com-
fort and quality of life for many cancer
patients.  Unfortunately, the expense of
the sustained release patented opioid
preparations limited accessibility, result-
ing in renewed interest in methadone as
a cheap generic alternative opioid ca-
pable of  providing sustained blood lev-
els with convenient dosing intervals.
In excess of 200,000 individuals are
managed at methadone treatment pro-
grams throughout the US.4  Until recently,
opioid treatment programs accounted for
the vast majority of methadone consump-
tion in the US.  Methadone prescribing
for pain conditions, while lagging initially,
has shown a consistent increase in prescrip-
tions throughout the 1990s.5  The Food
and Drugs Administration’s (FDA)
ARCOS (Automation of Reports and
Consolidated Orders System) data  on
methadone delivery in the US amounted
to 518,737 grams in 1997, increasing to
6,621,687 grams in 2006.  Mirroring the
rise in methadone consumption, was an
equally dramatic increase in unintentional
deaths linked to methadone.  Uninten-
tional prescription overdose deaths occur
predominantly with hydrocodone,
oxycodone, and methadone.  CDC data
for 1979-1990 revealed an average in-
crease in the death rate of 5.3%; however,
from 1990-2002 the unintentional drug
overdose rate increased by 18% per year.6
During that latter period, prescription
opioid deaths increased by 91%, with
heroin related deaths increasing by only
12% for the same period.  In 2002, pre-
scription opioids contributed to 4,451
deaths, as opposed to 1061 deaths linked
to heroin.  These statistics reveal the alarm-
ing increase in the misuse and abuse of
prescription opioids, which are second
only to marijuana as substances of abuse.
As indicated above, hydrocodone,
oxycodone, and methadone are the three
most common agents implicated in over-
dose deaths.7 Methadone has been in-
volved in approximately one-third of all
prescription drug overdose deaths, de-
spite the fact that it is prescribed far less
than oxycodone.
Several factors may account for the
apparent increased hazard.  First, metha-
done is extensively employed in the treat-
ment of chronic substance abusers.  The
presence of methadone may reflect con-
current polysubstance abuse in clients
undergoing methadone maintenance
therapy.  Second, methadone has a pro-
longed elimination profile, which may
prove uniquely hazardous when taken
concurrently with alcohol and other cen-
tral nervous system depressants.  Al-
though methadone doses of 80-120mg/
day are common in the management of
opioid addicts, the naïve abuser may po-
tentially develop respiratory depression
after a single 50mg dose.  Third, metha-
done is able to prolong the rate-corrected
QT interval (QTc) of the cardiac cycle,
potentially triggering a lethal torsades de
pointes arrhythmia, a form of polymor-
phic ventricular tachycardia.  Prolonga-
tion of the QTc appears to be dose-re-
lated, most evident when the methadone
dose exceeds 120mg daily.  However, the
potential for lethal drug combinations,
such concomitant therapy with various
antipsychotics, antibiotics, antidepres-
sants, antifungal agents, and a wide vari-
ety of other pharmacologic agents may
additively prolong the QTc or inhibit the
metabolism of methadone resulting in
marked elevation of the blood level.
Coexisting factors, such as familial pro-
longed QTc syndromes, hypokalemia,
hypomagnesemia, female gender, and
preexisting cardiac disease, are likely to
increase the risk of lethal arrhythmias.
METHADONE PHARMACOLOGY
Methadone is a lipid soluble, basic
compound that exhibits excellent
bioavailability.  Absorption after oral tab-
let ingestion results in peak blood levels
at around 3 hours, with approximately
85% absorption.  Methadone is a chiral
compound, with only the racemic mix-
ture available in the US.  R-methadone
isomer is a potent mu and delta opioid
agonist, and is available in Germany as a
distinct product.  S-methadone has no
mu-opioid activity; however, it does ex-
hibit some potentially useful properties
for the treatment of pain and addiction.
S-methadone is an antagonist of the N-
methyl-D-aspartate (NMDA) glutamate
receptor, which may play an important
role in reducing opioid tolerance, and in
providing analgesia much like ketamine.
S-methadone also appears to block the
reuptake of serotonin and norepineph-
In considering the
long half-life of
methadone in the
body, it is important
to recognize that
dosage
adjustments must
be made slowly.
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rine, which may contribute to analgesia
as well.  For these reasons, methadone is
often recommended for the management
of neuropathic pain.
Methadone exhibits a fairly large
volume of distribution, with a prolonged
elimination phase.  The elimination pro-
file reveals an initial alpha phase of 8-12
hours, followed by a very prolonged beta
elimination phase of 30-60 hours.  This
pattern accounts for the more frequent
every 8-hour dosing pattern required for
pain treatment vs. the once-daily dosing
employed in the treatment of addiction.
The prolonged lower blood levels ob-
tained with once-daily dosing are suffi-
cient to block opioid withdrawal, but are
inadequate for analgesia.  Elimination of
methadone occurs predominantly via
hepatic biotransformation.  The cyto-
chrome P450 (CYP) isozymes, predomi-
nantly CYP3A4, demethylate the parent
compound.  Other enzymes, including
CYP2B6 and CYP2D6 participate to a
lesser extent.8 Methadone accumulation
does not appear to be problematic in the
setting of renal failure or stable hepatic
disease.  Methadone appears to develop
large tissue reservoirs, which may con-
found the interpretation of blood levels
in overdose cases, due to re-equilibration
into the bloodstream.9
In considering the long half-life of
methadone in the body, it is important
to recognize that dosage adjustments
must be made slowly.  Steady state blood
levels are generally not achieved until af-
ter 4-5 half-life intervals.  Because  metha-
done may take up to a week to equili-
brate, rapid escalation of the dose can
lead to the development of toxicity 3 days
after the last adjustment.  Patients accus-
tomed to the rapid titration of most short-
duration opioids can be at risk if they are
not carefully educated to avoid self-titra-
tion and to adhere rigidly to the pre-
scribed dose.
TOXICITY
As with any opioid, methadone
shares a similar pattern of toxicity and side
effects, most of which are directly attrib-
utable to activation of an opioid recep-
tor.  Common toxic manifestations in-
clude: constipation, nausea, vomiting,
sedation, pruritis, bradycardia, and res-
piratory depression.  Respiratory depres-
sion is believed to contribute to most
opioid-related deaths.  Respiratory de-
pression is dose related, but varies greatly
between individuals, influenced by prior
opioid exposure, concomitant use of cen-
tral nervous system depressants, the in-
take of drugs that may alter the metabo-
lism of methadone, and co-existing con-
ditions, such as sleep apnea.  Some de-
gree of tolerance appears to develop to
the respiratory depressant effects of opio-
ids; however, this is incomplete, and evi-
dence suggests that worsening of sleep
apnea occurs in a dose-dependent fash-
ion.10 The one unique aspect to metha-
Table 1. Methadone Drug Interactions Contributing to
Cardiac Toxicity a
Class Interaction
ANTIBIOTICS Increase methadone levels through
CYP 450 enzyme inhibition (3A4);
Fluoroquinolones (ciprofloxacin, also have causal relation to QT
moxifloxacin) prolongation
Macrolides (erythromycin,
clarithromycin)
Decrease methadone levels through
Rifamycins (rifampin, rifapentine) CYP 450 enzyme induction
ANTIFUNGALS Increase methadone levels through
CYP 450 enzyme inhibition (2C9,
Ketoconazole, itraconazole, 2C19, 3A4)
voriconazole, fluconazole
ANTIDEPRESSANTS May contribute directly to QT
prolongation
Tricyclic antidepressants (amitriptyline,
desipramine)
Selective serotonin reuptake inhibitors
(fluvoxamine, sertraline, fluoxetine) Increase methadone levels through
CYP 450 enzyme inhibition (3A4, 2C,
2D6 to varying degrees)
ANTICONVULSANTS
Carbamazepine, phenytoin Decrease methadone levels through
CYP 450 enzyme induction (3A4)
ANTIOVIRALS
Efavirenz, nelfinavir, amprenavir, Decrease methadone levels through
darunavir CYP 450 enzyme induction (3A4)
Ritonavir May increase methadone levels
initially; decrease methadone levels
with prolonged use through CYP
enzyme induction (3A4)
ANTIPSYCHOTICS
Phenothiazines, haloperidol, droperidol, Additive inhibition of repolarization
risperidone, ziprasidone, quetipaine resulting in QT prolongation
a Not a complete list of all potential methadone/drug interactions.  Adapted from: Clinical Pharma-
cology Online. Methadone monograph – interactions.  Retrieved February 21, 2008. Available at
www.clinicalpharmacology.com and Hansten PD, Horn JR.  The Top 100 Drug Interactions – A
Guide to Patient Management.  2007 Edition.  Freeland, WA: H&H Publications; 2007.
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done is the prolonged rise in the blood
level, which may result in a more insidi-
ous onset of the respiratory depression.
Mounting evidence has shown a re-
lationship between methadone and pro-
longation of the QTc interval.11,12 Stud-
ies in asymptomatic patients receiving
methadone reveal a tendency toward pro-
longed QTc intervals, especially with
doses exceeding 120mg.13 However,
torsades has occurred in individuals over
a wide range of doses, in some cases as
low as 60mg, based on data reported to
the FDA.12 Intravenous administration of
methadone may be associated with a
greater risk of QTc prolongation, possi-
bly due to the preservative chlorobutanol,
which also inhibits the hERG potassium
channel.14  Based on this information,
screening electrocardiograms should be
considered in most individuals receiving
methadone in dosages greater than
120mg.  Serial electrocardiograms should
be considered as the dose level is esca-
lated to assess the QTc interval, particu-
larly when other pharmacologic agents
known to impact the QTc interval are
prescribed. (Table 1)
PRESCRIBING METHADONE
Methadone appears to be a useful
alternative in the management of refrac-
tory cancer pain.3,15,16 There is also con-
siderable support, at least from a mecha-
nistic point of view, for its use in the man-
agement of neuropathic pain refractory
to other interventions.2 Initiating metha-
done for pain treatment in the opioid-
naïve patient should begin with a small
dose of 2.5-5mg at 8-12 hour intervals.
The guiding principle should be “start
low and go slow”.  Small adjustments of
2.5 mg per day are reasonable in this set-
ting.  Remember that methadone peak
plasma levels will not achieve steady state
for 3 to 5 days in most individuals.  Fur-
thermore, as methadone tissue stores
build, the half life will tend to increase.
Most opioids display incomplete
cross-tolerance. When converting be-
tween oxycodone and morphine, the cal-
culated 24-hour equivalent dose should
be reduced by 20-30%.  However, with
methadone, the calculated 24-hour dose
may need to be reduced as much as 90%
or more.  The higher the preexisting dos-
age of opioid, the greater the reduction
in the recommended starting methadone
dose.  Two methods of rotation may be
employed when rotating to a new opioid.
The first involves “stop and go”, by halt-
ing the delivery of the previous opioid
and initiating a calculated equivalent 24-
hour dose in divided intervals, with a
supplemental dose for inadequate anal-
gesia.  The second approach is to gradu-
ally taper the existing opioid by one-third
daily, and gradually escalate a conserva-
tive dose of methadone 2.5-5mg every 8
hours.  This approach is probably more
convenient when dealing with patients
receiving intravenous opioids than oral
sustained release dose forms.  Several pro-
tocols for switching to methadone have
been published.17-21 The dose of the 24
–hour equivalent of the starting opioid
helps determine which protocol to use.
For example, one source used linear re-
gression to analyze 5 protocols and de-
velop a formula, referred to as the “rule
of 15.”22  This formula (estimated oral
methadone dose per day (mg) = oral
morphine equivalent dose per day (mg)
÷ 15 + 15) can be used for a patient tak-
ing daily equivalents of 60 – 1200 mg of
oral morphine.  Another formula should
be used for patients falling outside these
parameters.  These formulas are not ex-
act.  Rather, they provide a safe starting
point, or dose estimation, from which to
adjust treatment.  Patients need to be
educated regarding the toxic nature of
methadone, stressing the importance of
keeping their medication in a locked se-
cure location.  Individuals receiving doses
of 120mg or greater should be monitored
with serial electrocardiograms prior to
dose adjustments.  Patients receiving high
doses, greater than 300mg/day, are at risk
for cardiac events, and further escalation
in the dose may be inadvisable without
careful evaluation.
CONCLUSION
Methadone is an effective analgesic
with unique properties that set it apart
from most other opioids.  These unique
aspects, the prolonged duration of action,
NMDA receptor inhibition, and cat-
echolamine reuptake inhibition appear
to provide improved analgesia, but also
carry the risk of a unique toxicity profile.
When applied cautiously, methadone has
great value as an analgesic for cancer and
other persistent painful conditions
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Postoperative Pain Management for the
Opioid-Tolerant Patient
Frederick W. Burgess, MD, PhD, and Andrew Maslow, MD
As we approach the end of the Decade
of Pain Control and Research, healthcare
monitoring organizations, such as the
Joint Commission for the Accreditation
of Healthcare Organizations, have pro-
mulgated standards for the evaluation
and treatment of pain, thereby improv-
ing the documentation, assessment and
treatment of pain.  The medical profes-
sion has in turn provided greater access
to analgesic medications, especially the
opioid class.   Opioid prescribing and
consumption have soared, particularly in
the realm of cancer pain and other per-
sistent pain conditions.1 As a result, many
preoperative surgical patients present
with a history of long-term opioid con-
sumption and preexisting tolerance.
The success of chronic opioid admin-
istration for cancer pain suggested that an-
algesia could be maintained over sustained
periods in the majority of patients.  How-
ever, mounting evidence suggests that long-
term opioid use reduces opioid analgesic
efficacy pain and may lead to increased pain
sensitivity.  Doverty and associates, using the
cold pressor test pain model, documented
a reduced pain threshold and hyperalgesia
in methadone maintenance patients.2 This
population displays considerable cross-tol-
erance to morphine.  Although they will
receive larger doses of opioid than the
opioid naïve population, their pain control
is significantly poorer.3   Rapp and col-
leagues compared the pain response and
analgesic consumption of a series of sub-
jects treated with long-term opioids under-
going surgery to a matched control popu-
lation.4   Employing a liberal intravenous
patient-controlled analgesia regimen for
postoperative pain, they found that patients
taking long-term opioids consumed, on
average, 3 times more opioid.  Despite this
large opioid intake, pain control in the
chronic opioid group was significantly
worse than the matched controls.  The au-
thors concluded that pain scores in the
chronic opioid group do not entirely
reflecte the patient’s comfort level.
DeLeon-Casasola and colleagues noted a
similar pattern in postoperative surgical
patients using chronic opioids, who were
treated with epidural opioid infusions.5
They also found that chronic opioid users
required 3 times the usual epidural opioid
dose for adequate analgesia.
Pain scales tend to be consistently in-
flated in the persistent pain population.4
More global measures of patient distress
may be more useful in guiding treatment
than targeting specific pain score targets.6
Assessments of a patients’ ability to partici-
pate in their rehabilitation program, to
obtain restful sleep and, their amount of
suffering are useful to help guide opioid
administration.  Most patients will respond
honestly if asked whether their pain level is
tolerable.  Unfortunately, unrealistic expec-
tations of complete pain relief increase the
risk of respiratory depression and other
opioid-induced side effects.  While toler-
ance to the analgesic effects of opioid medi-
cations can develop rapidly, tolerance to
opioid side effects such as respiratory de-
pression, and constipation is less complete.7
Substantial evidence suggests hat good
perioperative pain control improves out-
come, hastens return to baseline function,
and reduces healthcare costs. For some
chronic opioid users, their pain may be di-
rectly related to their pending surgical in-
tervention, such as painful osteoarthritis
leading to joint replacement, or lumbar
spine surgery.  In most of these patients, the
surgical intervention will ultimately improve
their pain, but in the short-term, they
present considerable challenge to the anes-
thesiologist and surgeon.  The burden falls
on caregivers to satisfy their comfort needs
and elevate their function in the immedi-
ate postoperative period.  The following
discussion will review pain management
options in the perioperative period, with
emphasis on chronic opioid users.
ANESTHETIC OPTIONS TO REDUCE
POSTOPERATIVE PAIN
Anesthetics, aside from the opioids,
provide direct analgesic effects through
non-opioid pathways, or indirectly modu-
late the opioid receptors to reduce toler-
ance and improve opioid efficacy.  Examples
include nitrous oxide and ketamine.8,9 Both
are antagonists of the glutamate N-methyl-
D-aspartate (NMDA) receptor, which
modulates sensory neuronal activity in the
spinal cord.  The NMDA receptor appears
to play an important role in the amplifica-
tion of the sensory pain signal through a
mechanism referred to as “wind-up”.  In
addition, the NMDA receptor is involved
in the development of opioid tolerance.
Thus patients treated with nitrous oxide or
ketamine as part of their anesthetic regi-
men experience less postoperative pain and
require less opioid analgesic.10
In the early 1990s, “preemptive an-
algesia” (the early administration of anal-
gesics prior to the onset of pain) was
thought to disrupt the “wind-up” phe-
nomena at the spinal cord level and re-
duce postoperative pain.11  Local anesthet-
ics are the only pharmacologic agent ca-
pable of completely blocking pain sensa-
tions, at least temporarily, and have been
found to be useful in reducing opioid re-
quirements in some circumstances.  Local
anesthetics may be administered via
wound infiltration, nerve blockade, or cen-
tral neuraxis blocks (spinal or epidural).
Regional anesthetic techniques may be
used in the operating room, and may be
extended into the postoperative period
employing in-dwelling catheters for con-
siderable advantage.  Although preemp-
tive analgesia using local anesthetics has
been reported, this benefit has not been
consistently demonstrated.
No preemptive pain benefit has been
demonstrated with early (preincision)
administration of opioids.  While animal
models suggested that the administration
of opioids prior to surgical trauma could
reduce the intensity of pain during the
postoperative phase, it has been difficult
to replicate opioid preemptive analgesia
in humans.11  In contrast, some studies
have demonstrated the development of
increased postoperative pain and analge-
sic requirements in patients treated with
high-dose opioid infusions during sur-
gery.12  High-dose remifentanil and fen-
tanyl infusions appear to contribute to

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increased postoperative pain and opioid
consumption, suggesting rapid onset of
opioid tolerance during the early post-
operative period.12,13  The development
of rapid opioid tolerance is not inconsis-
tent with other animal models and clini-
cal studies which confirm the rapid on-
set of tolerance, as well as the develop-
ment of hyperalgesia with prolonged or
high-dose opioid exposure.14-16  Thus, a
balanced analgesic technique utilizing
nonopioid analgesic regimens, alone or
in combination with low-dose opioids,
may aide in preserving opioid efficacy,
reducing opioid consumption, and im-
proving postoperative pain control.
ALTERNATIVE ANALGESIC
STRATEGIES
Strategies to reduce postoperative
pain and escalating opioid use in chronic
opioid users need to consider individual
patient and surgical factors.  In most set-
tings, it is probably unwise to have the
patient stop his analgesic medications
prior to surgery.  Poorly controlled pre-
operative pain is associated with difficult
pain management in the postoperative
phase. This can be prevented by continu-
ing the regular pain medication already
prescribed.  The practice of stopping all
NSAIDS two weeks prior to surgery is to
be condemned.  Long half-life NSAIDS
may be discontinued in favor of shorter
acting agents, such as ibuprofen.
Ibuprofen need only be discontinued 24-
48 hours prior to surgery if bleeding is a
concern. An alternative approach is to
consider the use of celecoxib, the only
cyclooxygenase-2 inhibitor still on the
market, as it does not interfere with plate-
let function.  A single preoperative dose
on the morning of surgery and subse-
quent doses during the postoperative can
improve pain symptoms and potentially
diminish opioid requirements.17,18
As noted, some anesthetic agents can
improve pain and reduce opioid de-
mand, if incorporated into the patient’s
anesthetic plan.  A meta-analysis supports
the use of ketamine, 0.5mg/kg during
anesthetic induction or shortly before
incision to reduce opioid consumption
and side effects during the early postop-
erative phase.19  This may be uniquely
helpful in patients who were employing
chronic opioids prior to surgery, to re-
duce opioid tolerance.  In addition, ni-
trous oxide may be included as a compo-
nent of the anesthetic, because its action
as an NMDA antagonist appears to con-
tribute to improved postoperative pain
with few major side effects.9
Regional anesthetic techniques re-
duce postoperative pain and opioid con-
sumption.  The use of regional nerve
blocks, such as femoral, sciatic, and vari-
ous brachial plexus nerve blocks for ex-
tremity procedures can offer an extended
period of analgesia following surgery.
Epidural local anesthetic/opioid infusions
provide very effective analgesia following
thoracic or upper abdominal surgery.20
Benefits include improved pulmonary
function, a stronger cough, and, in some
studies, a reduced need for postoperative
mechanical ventilation.  Although most
complicated pain management patients
will require supplemental opioids, their
pain control will be substantially improved
by employing spinal or epidural analge-
sics.  Furthermore, attempts to eliminate
opioid analgesics in the chronic user prior
to surgery is not desirable, and increases
the risk of developing opioid withdrawal
symptoms, despite obtaining good pain
relief from central neuraxial opioids.  As a
general rule, chronic opioid users should
be maintained on their preoperative dose
of opioids during the postoperative
phase, at a minimum!  If no other anal-
gesic method is employed, it is reason-
able to anticipate that these patients will
require supplemental opioids exceeding
2-3 times their usual intake.
While the analgesic value of local an-
esthetics is well recognized when applied
directly for neural blockade, local anesthet-
ics may also be of considerable value as an
intravenous analgesic.  Intravenous
lidocaine has been employed in a variety
of chronic pain conditions.  Recent evi-
dence shows that intravenous lidocaine is
useful as a postoperative analgesic.  Patients
undergoing intestinal surgery treated with
a continuous postoperative lidocaine in-
fusion (2mg/min) experienced less pain
and obtained a more rapid recovery of
bowel motility following surgery.21
Lidocaine infusions for postoperative pain
are often limited to patients in monitored
settings due to preexisting nursing proto-
cols originally designed for cardiac ar-
rhythmia management.   However, as
more experience in this area develops, sys-
temic lidocaine administration may find
an important role as a valuable postopera-
tive analgesic adjunct.
Alpha-2 adrenoceptor agonists, such
as clonidine and dexmedetomidine can
improve pain management significantly.22
Clonidine has been employed as an epi-
dural analgesic for the treatment of intrac-
table cancer pain and other chronic pain
conditions.  Recently, dexmedetomidine,
an a-2 adrenoceptor agonist which is
nearly 8 times more selective for the a-2
receptor than clonidine, is available for
intravenous infusion for use as a sedative/
analgesic.22  Initially exploited as a seda-
tive in the critical care setting,
dexmedetomidine offers a number of
clinical advantages over other sedative
agents in the perioperative period.25
Stimulation of pre-junctional a2 adrener-
gic receptors inhibits norepinephrine re-
lease, and also contributes to increased se-
cretion of GABA from the Locus Ceruleus
in the brainstem, resulting in reduced
anxiety, sedation and a ‘natural’ sleep
state.24  Stimulation of a2 receptors of the
intermediolateral cell column and sub-
stantia gelatinosa of the spinal cord inhib-
its the release of Substance P resulting in
analgesia.  When used alone, it does not
result in respiratory depression.  In addi-
tion, it is capable of producing analgesia,
a reduction in blood pressure, and a rela-
tive bradycardia, all attractive features in
the perioperative patient.
Dexmedetomidine analgesia is not as pro-
found as the opioids, but does reduce the
consumption of opioids and other anal-
gesics.  Dosing varies with the clinical sce-
nario. Intravenous doses of 0.2-0.5 mcg/
kg may be administered as analgesic
supplements, alone or in conjunction with
a continuous infusion of 0.2-1.0 mcg/kg/
hr.  Too rapid administration of larger
doses of dexmedetomidine may produce
transient elevations in blood pressure, usu-
ally followed by a decline.  Doses exceed-
ing 1mcg/kg/hr do not cause a decline in
blood pressure, and may even cause a small
The practice of
stopping all NSAIDS
two weeks prior to
surgery is to be
condemned.
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rise in pressure.  Dexmedetomidine will
not entirely replace the need for opioids,
but may be helpful as an opioid adjunct,
reducing side effects and improving anal-
gesia during the perioperative period.
Another atypical analgesic class, are
the gabapentinoids.  Although introduced
as an anticonvulsant, gabapentin, and the
newly available analog pregabalin, have
found considerable use as analgesics for
various neuropathic pain conditions.26
Gabapentin has recently been exploited
as a supplemental analgesic for
perioperative pain.27  A preoperative dose
of gabapentin (900-1200 mg) followed
by additional doses during the postopera-
tive period allow a reduction in opioid
consumption.  However, in some trials,
gabapentin appeared to contribute to in-
creased postoperative sedation and dizzi-
ness.  There was evidence of a reduction
in opioid related side effects and in over-
all opioid consumption during the first 24
hours.    Gabapentin may be considered
as an adjunct analgesic, but the evidence
is inadequate to recommend widespread
adoption.  Further study will be needed
to determine which surgical procedures
will benefit from this medication, and the
optimal dose and duration of treatment.
CONCLUSION
Patients consuming high-dose opio-
ids on a chronic basis present consider-
able challenge during the perioperative
period.  While the opioid class remains
our most effective means to provide pain
relief, alternative analgesic approaches
can be extremely helpful in improving
pain control instead of, or in balance with
opioids.  By controlling factors that in-
fluence postoperative pain, such as
proper preoperative preparation of pa-
tient expectations, continuing the use of
preoperative analgesics, appropriate se-
lection of the surgical procedure, and
utilization of alternate pain relieving strat-
egies, pain control and patient satisfac-
tion can be achieved in the most chal-
lenging patient.  As in other areas of
medicine, combination therapy can of-
ten provide the best effect with the few-
est adverse reactions.
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An estimated 5% to 33% patients in pri-
mary care settings have chronic non-can-
cer pain. 1 As many as 90% of patients in
pain management settings receive opioid
medications.2, 3 Opioids are powerful and
effective analgesics which are important in
the management of moderate-to-severe
chronic pain that is not controlled with
non-pharmacologic therapies and non-
opioid analgesics. Primary care practitioners,
who do much of the long-term opioid
prescribing, are often uncomfortable pre-
scribing opioids  to patients with chronic
pain, because of the perceived risks of opioid
dependency, addiction, abuse and the po-
tential  legal consequences.4 Also, opioids
may interact with other prescribed medi-
cations or illicit chemicals (i.e. benzodiaz-
epines, alcohol), which may result in life-
threatening conditions. Further, patients af-
flicted with persistent pain tend to under-
estimate their medication use and provide
incorrect information about their illicit
drug usage. In a recent retrospective analy-
sis of data from 470 patients who had urine
screening at a pain management program
in an urban teaching hospital, 45 % of the
patients had abnormal urine screens (either
for the absence of the prescribed opioid or
having an illicit substance in their urine). 5
Therefore, random or regular drug testing
is an essential component of pain manage-
ment with opioid medications as recom-
mended in the model guideline for the Use
of Controlled Substances in Pain Manage-
ment issued by the Federation of State
Medical Boards. 6
URINE DRUG TESTING
A urine drug test (UDT) is a techni-
cal examination of urine samples to deter-
mine the presence or absence of specified
drugs or their metabolized traces. Urine has
a 1- to 3-day window of detection for most
drugs. Recent use of prescription medica-
tions (e.g., opioids, benzodiazepines, am-
phetamines, barbiturates) and illegal sub-
stances (e.g., heroin, cocaine, marijuana,
phencyclidine) can be detected in patients’
urine.7,8 It also is low cost and non-invasive,
compared to blood testing. Depending on
The Use of Urine Drug Testing To Monitor Patients Receiving
Chronic Opioid Therapy for Persistent Pain Conditions
Tahir Tellioglu, MD

the need, the clinician requests testing
whether the presence of any particular sub-
stance or group of substances is suspected
or expected. One of the commonly used
UDT panels is called “Federal Five” drugs
or drug classes (marijuana, cocaine, opiates,
PCP, and amphetamines), tested in federal
employees.9 Other drugs can be added to
the list, depending on the need and the
availability of the laboratory technique
(methadone, propoxyphene, benzodiaz-
epines, oxycodone, and barbiturates).
BENEFITS AND LIMITATIONS OF
URINE DRUG TESTS
For most clinical applications, initial
UDT is usually done with class-specific im-
munoassay drug panels. The immunoassay
technique, either laboratory based or at the
clinic (e.g., "dip-stick" testing), is a rapid
testfor drugs in the urine, at lower cost. (Fig-
ures 1 and 2) It detects only the classes of
drugs such as barbiturates, or opioids, but
typically does not identify individual drugs
within a class. Further, its ability will vary
according to the drug concentration in the
urine and the assay’s cutoff concentration.
Immunoassay is highly predictive of cocaine
and its primary metabolite, benzoylecgonine.
Because of the cross-reactivity problems,
immunoassay is less reliable for amphetamine/
methamphetamine. Immunoassay is very re-
sponsive for morphine and codeine, but again,
is unable to distinguish which is present. They
also usually give false negative results for semi-
synthetic/synthetic opioids such as oxycodone,
oxymorphone, buprenorphine, fentanyl, and
methadone. Specific immunoassay tests for
some semisynthetic/synthetic opioids will even-
tually become available.
Single-use immunoassay devices are
available for urine testing of common classes
of misused drugs. 10 They are practical, easy
to use, offer rapid results, require little train-
ing and are inexpensive. However, they of-
ten are inadequate in opioid management
since they only identify the drug class, not
the presence of a specific drug. Further, the
devices may lack adequate quality assurance
and quality control (e.g., the integrity of the
test reagents following transportation and
storage).
Laboratory-based UDTs are used to
separate the different components and spe-
cifically identify the components in a speci-
men.  These techniques, including gas
chromatography/ mass spectrometry
(GC/MS) and high-performance liquid
Figure 1. Urine Drug Testing Algorithm for patients on opioid pain medications.
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chromatography (HPLC), can confirm a
specific drug. Laboratory-based UDTs can
also identify drugs that are not detected by
immunoassay methods (such as the semi-
synthetic opioids hydromorphone,
hydrocodone, oxycodone and
oxymorphone).
The cost is a concern in urine testing.
Unselective UDT (immunoassay technique)
is usually much cheaper than the laboratory-
based UDT. Among these, dip-stick testing is
a rapid test for drugs in the urine, and it has
lower cost ($5-10 per test). (Picture 1) On
the contrary, the average costs for the labora-
tory-based UDT are between $100 to $ 200
per test for self-paying patients in Rhode Is-
land. (Reimbursement rates for the insured
vary depending on the insurance). Because a
test is relatively expensive does not necessarily
mean that it is not cost-effective. Cost-effec-
tiveness depends on the speed of obtaining
results, the interpretation and clinical use
made of them, and, above all, their analytical
reliability. While commercial strips eliminate
the need for test tubes and incorporate stan-
dardized reagents, the instructions and warn-
ings about storage and use are often ignored,
and multi- reagent strips are especially liable
to be used incorrectly.
URINE TESTING FOR ALCOHOL
ABUSE
Alcohol combined with an opioid
such as methadone increases the risk of
excessive sedation. It is important for prac-
titioners to test routinely for alcohol, to
encourage and educate patients of its con-
sequences, and avoid providing opioid
medication to patients who abuse it. Al-
cohol has a short duration in the body and
is detectable for less than 12 hours.
While most alcohol is metabolized by
alcohol dehydrogenase to carbon dioxide
and water, a small portion is conjugated to
ethyl glucuronide (EtG). EtG can persist in
the urine for several days (up to 80 hours).
It has been reported as a sensitive and spe-
cific marker to detect alcohol use 11, and the
test has recently become commercially avail-
able. However, alcohol is present in many
non-beverage products that can produce a
positive result. The use of an EtG test in de-
termining abstinence lacks sufficient speci-
ficity for use as primary evidence.
FREQUENCY OF TESTING
It is generally accepted that each pa-
tient should have drug testing during as-
sessment for chronic opioid treatment. The
frequency of UDT is based on the patient’s
condition: testing should provide enough
warning time to respond to a potential abuse
or misuse. Some drugs such as cocaine can
be detected in the urine for 3 days after the
last dose, therefore patients may need fre-
quent testing (twice-a-week) to detect such
usage. The presence of medications which
can interact with the opioids  -such as ben-
zodiazepines-  should be detected early and
their risks and benefits analyzed and docu-
mented. Regular testing should be per-
formed more frequently early in treatment,
and then continued randomly when pa-
tients are stabilized.
URINE COLLECTION
In general, 30 ml urine sample is ad-
equate to complete the testing and satisfy
requirements. The temperature of a urine
sample within 4 minutes of voiding should
fall within the range of 90ºF to 100ºF.
Urinary pH should remain within the
range of 4.5 to 8.0. Concentrated urine
samples are more reliable than dilute
samples. Therefore, urinary creatinine less
than 20 mg/dL is considered dilute; less
than 5 mg/dL is not consistent with hu-
man urine. Some patients may falsify test
results for secondary gain. Urine samples
outside of these ranges should be discussed
with the patient and/or the laboratory, as
necessary by sound treatment ethics and the
overall goals of the program. Direct obser-
 Table 1.  Advantages and disadvantages of types of urine drug testing methodology
for patients on opioid pain medications
Type: Advantages Disadvantages
Immunoassays • Provide rapid results • lacks specificity to determine which drug
• small quantities of substances can be detected in a class is present
• permit onsite analysis of test specimens • problems persist about the chain of
custody, provision, stability, and storage
of samples
• have limitations such as increased cost
or reduced accuracy.
• Some State regulations disallow onsite
test analysis.
Chromatography • Can determine which drug in a class is present • requires relatively large amounts of drugs
in the sample in specimens require laboratory setting
and special facilities
Table 2. Checkpoints
• Patients maintained on opioid pain medications should be tested regularly
for alcohol and common illicit substances including marijuana, opioids, ben-
zodiazepines, amphetamine, and cocaine.
• Urine drug testing remains the most common method of drug testing; how-
ever other drug testing methods are developed.
• Training and educating should be provided to staff members about the ben-
efits and limitations of drug tests.
• Unfavorable drug test results should not be used punitively but should be
seen as an opportunity to discuss and modify the treatment approaches
accordingly.
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vation of urine collection, temperature
strips, adulterant checks, and other meth-
ods should be used when possible to en-
sure test validity. All urine samples are com-
monly checked for pH and temperature.
In case there are further concerns regard-
ing the sample validity, the ordering physi-
cian may request additional analyses such
as urinary creatinine and adulterant checks.
INTERPRETING AND USING DRUG
TEST RESULTS
UDT is a useful clinical tool to docu-
ment compliance, stability and progress of
the treatment. Test results can even help pa-
tients to improve social and legal problems.
Abnormal results help identify addiction or
drug misuse. Test results should be docu-
mented in patient records along with appro-
priate justifications for subsequent treatment
decisions. In the event that the UDT results
are abnormal or inconsistent, patients should
be informed immediately and should be
given an opportunity to discuss these results
with the clinician. No treatment decisions
should be based on a single test result.  Labora-
tory errors or false positive results due to in-
teractions with other substances are not un-
common. False positive urine immunoassay
tests have been  reported for cannabinoids
in patients receiving proton pump inhibi-
tors, such as pantoprazole.12 However, a con-
firmatory test such as GC/MS will not verify
the positive immunoassay result. It is also
important to remember that certain benzo-
diazepines, such as clonazepam, synthetic
opioids, such as methadone and oxycodone,
are not detected by all immunoassays tests.
Those must be specifically requested when
ordering a UDT.
Since the UDT is done for the patient’s
benefit, abnormal results should not be
used to force patients out of treatment.
Reports indicating substance abuse should
signal the need for a medical review of medi-
cation dosage and for intensification of
counseling and education. However, per-
sistent abnormal results (use of other opio-
ids and other substances, or the lack of the
prescribed opioid in the UDS) should gen-
erate a review of a patient’s opioid treatment
and may require referral to a substance
abuse specialist.
SUMMARY
Urine testing is a practical, inexpensive,
and valuable tool in general medical prac-
tice for patient guidance, treatment plan-
ning, and dosage determination in opioid-
treated chronic pain patients. (Table 2)
However, UDTs are under-utilized in clini-
cal practice. In a recent survey among 248
primary care practitioners, only 6.9 % re-
ported obtaining this test before prescrib-
ing opioids and only 15 % performed urine
toxicology tests on patients already prescribed
opioids. 4 Since the UDT is mainly done for
the benefit of the patient, the test results
should not be the only means to detect sub-
stance abuse or monitor treatment compli-
ance. Katz et al suggested that behavioral
monitoring and UDTs for patients receiv-
ing chronic opioids creates a more compre-
hensive monitoring system than either alone.
2  Inappropriate testing and overreliance on
laboratory results would detract from the
clinical management of and damage the
clinical relationship with the patient. There-
fore, training and education about the ben-
efits and limitations of drug tests are essen-
tial to help staff members understand the
importance of using test reports appropri-
ately. This would also help the practitioners’
concerns of iatrogenic addiction or relapse
of previously addicted patients.
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Figure 2: The 5-Panel Drug Screen Test
Card, detects 5 different drug categories,
displaying 5 separate results. The absorbent
Test Strips are dipped in urine and
removed. After 5 minutes, results are
displayed in each of 5 Results Windows.
2 Red Lines = Negative.
1 Red Line = Preliminary Positive.
5-Panel
Drug Test
Results
Window
Absorbent
Test Strips
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Recurring Meningitis: Recurrence After Suppressive
Therapy—Can We Call for Life-long Prophylaxis?
Venkataraman Munusamy, MD, Melissa Nothnagle, MD, and Najam Zaidi, MD
The Creative Clinican
Mollaret’s meningitis is a form of recurrent benign lymphocytic
meningitis characterized by recurrent episodes of fever and
meningismus that resolve without treatment.1 Though it is most
commonly associated with herpes simplex virus (HSV) type 2,2
rare cases have been attributed to HSV-1,3 Epstein-Barr virus4
and other infectious or inflammatory conditions.
CASE REPORT
A 44-year-old female with a history of asthma, depression,
irritable bowel syndrome, hypothyroidism, and recurrent men-
ingitis presented to the emergency department of Memorial
Hospital of Rhode Island in August 2007 with several hours
of headache, nausea, vomiting, fever, neck stiffness and gener-
alized muscle aches. She had no other neurological, urinary,
cardiac, respiratory, gastrointestinal or dermatologic symptoms.
She denied any recent outbreak of herpes vaginalis or labialis.
Her medications included albuterol, levothyroxine and
sertraline. She declined any recent use of antibiotics.  She had
been in a monogamous relationship for the past ten years.
On exam she had a temperature of 100.2° F and a posi-
tive Kernig’s sign. Fundoscopic exam was normal. Skin, oral,
genital mucosa, joints and extremities were normal.  Cerebrospi-
nal fluid analysis (Table 1]) showed pleocytosis with a predomi-
nance of lymphocytes. Cerebrospinal fluid PCR was positive
for HSV-2 Glycoprotein G gene. CT of the brain was normal
except for asymmetry in the region of the quadrigeminal plate
system in the cerebellar vermis. This is likely a congenital ab-
normality rather than an epidermoid cyst, rarely implicated in
recurrent meningitis.
The patient reported five prior episodes of aseptic menin-
gitis, in 1987, 1990, 1992, 2000 and 2003. In 1987, she had
an outbreak of herpes vaginalis, followed a few weeks later by
the first episode of aseptic meningitis. The 1992 episode was
preceded by herpes labialis, the 2000 episode by herpes
vaginalis. She had no herpetic lesions with any of the other
episodes.  We obtained records from her 2003 hospitalization,
at which time CSF- PCR was negative for HSV-1 and 2, and
she was treated empirically with intravenous ceftriaxone and
acyclovir. Ceftriaxone was stopped after the CSF was culture-
negative for 48 hours. Although the CSF-PCR did not detect
viral DNA, the episode was diagnosed clinically as recurrent
HSV meningitis. She received intravenous acyclovir 750 mg
three times a day for two days, to which she responded readily.
This was followed by oral valacyclovir, 1 gram every 12 hours,
to complete the 14 day course. The patient was discharged on
valacyclovir prophylaxis 1 gram PO once daily for a year, as
suppressive therapy to prevent recurrence. Early in therapy,
valacyclovir was changed to acyclovir, due to abdominal pain
and increased cost. She completed her suppressive therapy in
March 2004. The patient was not tested for the asymptomatic
virus shedding between episodes.
During the current episode, the patient was treated em-
pirically with intravenous acyclovir 800 mg thrice daily; this
resulted in rapid relief of headache and resolution of fever.
After two days this was changed to oral valacyclovir 1 gram
every 12 hours to complete a 14-day course of antiviral treat-
ment. We advised the patient that valacyclovir would be the
best choice for subsequent suppressive therapy, due to its greater
bioavailability compared with acyclovir; however, given her
history of side effects with valacyclovir, she opted for suppres-
sion with acyclovir.
DISCUSSION
A large number of cases of Mollaret’s meningitis have  been
reported, and some authors speculate that the incidence might
increase. When new HSV-2 infection occurs in the absence of
HSV-1 antibodies, higher rates of complications and recur-
rences are noted.5  In light of decreasing HSV-1 seroprevalence
in the United Kingdom6 and other developed countries, Davies
and colleagues suggest that patients in these areas will be more
likely to develop complications of HSV-2 such as recurrent
meningitis.7 Although the exact cause of recurrent episodes of
HSV-associated meningitis is unknown, Sato and colleagues
have suggested a low immune response secondary to immune
evasion by HSV-2 as a possible mechanism.8
When Mollaret’s meningitis occurs frequently, it can be
Table 1. CSF-Analysis
Year Biochemical Cell Gram stain/ PCR
analysis analysis cultures
Glucose Protein RBC/ WBC/ Lymphs Gram stain, Lyme IgG, HSV 2
mg/dl mg/dl mm3 mm3 % IgM, Cryptococcus, Glycoprotein G gene
Bacterial/Viral Culture
2003 47 52 7 333 87 Negative Negative
2007 49 109 9 312 71 Negative Positive
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mistaken for chronic meningitis, resulting in multiple hospi-
talizations with extensive diagnostic testing before establish-
ing a definite diagnosis. Depending on the severity of the
patient’s illness, length of hospitalization may range from 3
to 15 days, with charges estimated to be $6000.9 With im-
provement in the sensitivity of PCR and its decreasing cost,
early PCR has a key role in the management of patients with
recurrent aseptic meningitis.10  In addition to preventing ex-
cessive testing and repeat hospitalizations, early diagnosis with
PCR can facilitate focused management with oral valacyclovir,
instead of IV acyclovir, the current customary practice.11 We
propose this in light of evidence from a randomized controlled
trial which suggests that the bioavailability of high dose oral
valacyclovir is comparable to the levels achieved with IV
acyclovir.12,13 The decision of whether to treat on an outpa-
tient basis or a short inpatient stay is best left to the physician’s
assessment of individual cases. Oral antiviral therapy might
also be beneficial in cases that are preceded by herpes labialis
or vaginalis.10
In our patient, the sixth recurrence occurred two years
after completion of 12 months of suppressive antiviral therapy.
Some authors have noted a decrease in the frequency of at-
tacks of recurrent aseptic meningitis with prophylactic antivi-
ral therapy,14 but no study has been done to demonstrate
whether it can prevent recurrence altogether. The failure of
suppressive therapy in our case could be attributed to acyclovir’s
decreased bioavailability only, given the fact that the patient
assured compliance to the prescribed suppressive regimen.
A comprehensive literature search found no reports of
recurrence of Mollaret’s after suppressive therapy. For our pa-
tient the current treatment options would be starting antiviral
medications at the sign of first meningitis attack or long-term/
life-long suppressive therapy. The duration of suppressive
therapy in patients with recurrences after suppressive therapy
is yet to be studied and formulated.
Physicians must consider cost, side effects, and dosing
schedule of antivirals to ensure optimal adherence to the pro-
phylactic regimen.15 (Table 2)  Given that our patient had
recurrences approximately every three years, continuous pro-
phylaxis may have been cost-effective if it prevented repeated
hospitalizations for each episode.9 Though Mollaret’s menin-
gitis is uncommon, thoughtful management of recurrent at-
tacks with early PCR and long-term antiviral prophylaxis may
help patients avoid costly workups and recurrent hospitaliza-
tions.
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Table 2. Drug Cost and Dosage16
Drug Suppressive Approximate cost per
therapy dose month (US dollars)
Acyclovir 400  mg $28.99
twice daily
Valacyclovir 1000 mg $337.40
once daily
Famciclovir 250 mg $199.98
twice daily
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For an elderly patient, hospitalization can herald a cascade of
admissions and progressive functional decline.  Readmissions,
often defined as those that occur within a specified time frame
after discharge from an index admission, are particularly fre-
quent among patients initially admitted with congestive heart
failure, chronic obstructive pulmonary disease, myocardial in-
farction, diabetes, and stroke.  In addition to the deleterious
effects of the hospitalization itself, the act of transferring pa-
tients back and forth between healthcare settings creates an
opportunity for medical errors and miscommunication.1  With
shorter hospital stays and an increasing prevalence of
hospitalists, the discharge transition is fraught for elderly pa-
tients with multiple chronic conditions.  Healthcare staff may
relay information about patients’ medical histories, medications
and allergies, and prior testing late, incorrectly, incompletely,
or not at all.  This transition gap is receiving recognition at all
levels of patient care delivery, and the Centers for Medicare &
Medicaid Services has targeted care transitions and hospital
readmissions as areas needing quality improvement.  More and
more, rates of readmission to the hospital are perceived as mark-
ers for quality of care.2
Over the last fifteen years, investigators have undertaken
a variety of studies to understand why particular diseases and
patient subgroups are at higher risk for readmission.  They have
proposed different interventions to ameliorate the transition
from the hospital. Unfortunately, it is difficult to know what
works.  Categorizing the possible interventions is challenging
because of marked heterogeneity in every aspect of the effort.
For example, some investigators begin when patients are first
admitted, while others focus on patients’ arrival at their first
post-discharge clinic visit.  More ambitious programs seek to
pursue change at multiple points between admission and dis-
charge.  This article will discuss some of the more successful
interventions.
PRE-DISCHARGE INTERVENTIONS
Many interventions target patients while they are still in
the hospital. Patients may be assessed for risk of poor outcomes,
educated about their condition, trained on self-management
skills, evaluated by geriatric consultants, or given follow-up ap-
pointments before leaving the hospital.  Interventions often
include the patients’ caregivers in the patient education and
discharge planning.
Koelling and colleagues provide an example of a success-
ful pre-discharge intervention in patients admitted with con-
gestive heart failure.3  The researchers compared standard dis-
charge care with the addition of a one-hour, one-on-one teach-
ing session with a nurse educator.  The session focused on the
principles of heart failure and the rationale for therapy, dietary
recommendations, and self-management strategies.  With this
intervention, they halved heart failure readmissions within 180
days of discharge.
POST-DISCHARGE INTERVENTIONS
The majority of transition interventions in the literature
take place after hospital discharge.  Typically these incorporate
a home visit, often by an advanced practice or specially trained
nurse. Depending on the study, a variety of medical personnel
(physicians, pharmacists, physical therapists) might also per-
form patient assessments, measure vital signs, and make man-
agement recommendations.  In addition to patient visits and
recommendations, providers also perform medication recon-
ciliation, educate patients and their caregivers, facilitate com-
munication with patients’ primary care physician or specialists,
or work on self-management skills.
Disease management programs often provide the frame-
work for this approach. Young and colleagues found that in
patients discharged after myocardial infarction they reduced
readmissions by about half by using a protocol that included
six home visits by a nurse trained in cardiac care, a standard-
ized assessment checklist, communication with primary care
physicians, and patient education.4
TELEHEALTH INTERVENTIONS
Telehealth interventions are an emerging strategy to pre-
vent readmissions.  This category represents a variation of post-
discharge home care intervention, but instead of a nurse visit-
ing patients’ homes, the assessment and communication occur
remotely, usually by telephone.  These programs range from
unstructured telephone calls to multiple calls with the goal of
teaching self-management skills, promoting medication adher-
ence, and adjusting therapies based on symptoms.  Other in-
terventions provide in-home instruments to allow daily mea-
surement of weight, blood pressure, heart rate, and rhythm,
which patients then transmit over a telephone line.
One successful telehealth intervention included three
months of remote monitoring of patients with angina and con-
gestive heart failure.5  The program included weekly video
conferencing to assess patients’ progress and to provide educa-
tion; blood pressure and weight were transmitted daily over a
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telephone line.  The investigators reduced readmissions by a
third during this period, with much of the benefit in the pa-
tients with angina.  A systematic review of home monitoring
for patients with heart failure reported a positive impact on
hospital readmissions, as well as emergency department visits
and quality of life.6
MULTIDIMENSIONAL INTERVENTIONS
Multidisciplinary, multidimensional interventions address
several points along the patient pathway and incorporate many
of the modalities discussed above.  These are often intensive,
both in time and resources; and almost all include advanced
practice nurses.  In one of the best-known studies in this cat-
egory in older patients with congestive heart failure, Naylor
and colleagues reduced readmissions by a third.7  Specially
trained nurses visited patients within 24 hours of their index
hospital admission and then daily while the patients were hos-
pitalized.  They performed a comprehensive assessment of pa-
tients and caregivers, spearheaded discharge planning, coordi-
nated care among the patients’ hospital and outpatient physi-
cians, and assisted with medication regimens.  They then per-
formed a home visit within 24 hours of discharge and weekly
for the first month.  The nurses were also available by tele-
phone 7 days a week.
Coleman’s group also demonstrated a substantial decrease
in readmissions by incorporating an advanced practice nurse
in a multidimensional intervention.8  Similar to Naylor’s study,
the nurse met with patients while they were in the hospital,
made home visits, and helped patients manage their medica-
tions.  In Coleman’s work, however, the nurse acted as a “coach”
for patients and their caregivers; nurses did not participate in
medical management and were not involved as another
healthcare provider.  For example, the nurse encouraged the
patients to call their primary care physician if questions arose
and rehearsed the upcoming encounter to help patients ar-
ticulate their needs.
CHALLENGES IN THE FIELD
Judging the generalizability of a particular intervention
is challenging. Successful transition interventions may rely on
one or two specific nurses or may address a shortcoming in a
particular delivery network.  In addition, much of the re-
search is coming from abroad, and different health care sys-
tems, particularly single-payer systems, may produce differ-
ent outcomes than a similar intervention in the United States.
Many of the interventions that appear to work in one study
will show no significant effect in another.  Some discharge
interventions have actually been associated with an increase
in readmission rates.9
Additionally, the studies vary in the duration of the inter-
vention, and in the frequency and intensity of patient contact.
The measured endpoints vary from study to study.  Although
this discussion focuses on readmissions, studies also examine
other clinical factors (e.g., mortality, medication use, guideline
adherence, and functional status), healthcare utilization (e.g.,
days in hospital when readmitted, multiple readmissions, emer-
gency department visits, and total costs), knowledge of disease
management, quality of life, patient satisfaction, and caregiver
burden.  Lastly, the number of patients included in each study
is often small, and projects may be underpowered to detect
meaningful results.  Although researchers have performed sys-
tematic reviews and meta-analyses to capture these effects, the
results are often equivocal.
SUCCESSFUL ELEMENTS
Most systematic reviews of these transition interventions
cautiously report some evidence of their efficacy.10  Interven-
tions that include both a pre-discharge and a post-discharge
component and interventions that include some aspect of pa-
tient education and self-management seem to be the most ben-
eficial.11  Early post-discharge involvement and frequent con-
tact also have been cited as important elements in improving
clinical outcomes.12
Encouragingly, almost all interventions which measure
cost show a decreased cost associated with performing the
intervention, regardless of whether the number of readmis-
sions had been reduced.  This is because often investigators
are able to demonstrate a decrease in the number of days
patients stay in the hospital when readmitted or a decrease in
“multiple readmissions.”  Cost-effectiveness is a particularly
compelling outcome when investigators include total
healthcare costs in their calculations, not just hospital costs.
Ironically, despite the benefits and likely cost-effectiveness,
hospitals may actually profit from readmissions.  Consequently,
It may be reasonable to target health insurers as potential
sponsors and to emphasize the link to quality of care to create
incentive in reluctant participants.
UPCOMING DEMONSTRATIONS
The Centers for Medicare & Medicaid Services (CMS)
have focused on care transitions in their 9th Scope of Work for
quality improvement.  In the coming months, they will select
18 states to create demonstration projects aimed at reducing
readmission rates.  These interventions will address system-level
weaknesses, specific diseases that carry high risk of readmis-
sion, and drivers of local readmission rates.
CONCLUSION
Readmissions after a hospitalization are common in the
elderly, and certain diseases, such as congestive heart failure,
are associated with a particularly high readmission rate.  There
is an enticing array of potential interventions to ameliorate this
problem - from a simple telephone call after discharge to a
multidisciplinary, multidimensional year-long intervention - and
many appear promising in reducing readmissions and lower-
ing costs.  Future research should attempt to standardize inter-
vention taxonomy, design, and outcome measures to facilitate
comparison across multiple protocols.  In addition, more in-
vestigation is required to determine which aspects of the multi-
dimensional interventions are the most effective.
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Rapids by Louise Giguere
Like a river, the natural flow of life
the source, what force, the majesty,
the depth, making its mark, surrounds,
the edges,  its determined course,
        profound.
It turns, it bends, smooth as glass,
a willowy reed, like an innocent lass,
lulled, to the sound of motion, floating,
mellowed, unaware of the gradual change.
The range, the increasing turbulence,
the broken sound, the uneven obstructions
not budging, but judging, the current of breath,
the forecast, the charge, the venous protest
The slow boil fury of cold foam,
oscillates, blinding,
rapt, treasonous  tears
       It’s calling.
The aqueous energy stirred,
straight  through.
delving deep, deeper, the unfamiliar,
       the rapids they were.
Cresting, the rapid phase, leveling,
the waters calmed, gently flowing,
recalling, the feelings,
the squalor of reversing tides,
       on its way.
The birth, the stream, the flexing range,
fountain head fluxes, forward,
to the great somewhere.
The rapids remembered, like a river felt,
life’s blood, the natural flow of life,
navigating, nearing the source, wending,
wild and winsome, the greatest course,
Rapids, once again, surrenders.
To be, the current, the force,
      The open seas
The author, who lives in Coventry, has written this poem around
her stroke. She writes:  “‘Rapids’ is a metaphor about a mindset
and emotional well being, while paralleling the assault on the
blood vessels leading to the actual stroke experience.  The poem
continues with recognition, acceptance, change, and finally
ongoing emotional and physical recovery.”  
CORRESPONDENCE:
Louise Giguere
e-mail: Lougig579@yahoo.com
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Circumstances of Suicide Death in Rhode Island 2004-2006
Wendy Verhoek-Oftedahl, PhD, Edward F. Donnelly, RN, MPH, Miriam Fenton, and Thomas Gilson, MD
RHODE ISLAND DEPARTMENT OF HEALTH  •  DAVID GIFFORD, MD, MPH, DIRECTOR OF HEALTH EDITED BY SAMARA VINER-BROWN, MPH
Suicide has been identified as one of three top injury prevention
priorities in Rhode Island (RI).1 In 2005 suicide was among
the five leading causes of death for all people in the US age
10 to 54 years as well as for RI residents in this age group.2
Circumstances of suicide deaths have not been well studied
in RI, missing an important opportunity for prevention.  In
2003 the Centers for Disease Control and Prevention (CDC)
funded Rhode Island to participate in the National Violent
Death Reporting System (NVDRS), a surveillance program
for intentional injury deaths.3 The NVDRS collects detailed
demographic and circumstance data on homicides, suicides,
deaths of undetermined intent, and unintentional firearms
deaths according to standardized procedures and protocols.
Currently, 17 states are participating.  The Rhode Island (RI),
component known as the RI Violent Death Reporting Sys-
tem (RIVDRS), began data collection in 2004.  This is the
first detailed report of suicide circumstances based on
RIVDRS data.
METHODS
Data on suicide deaths that occurred in RI from 2004-
2006 were extracted from RIVDRS.  RIVDRS contains infor-
mation on decedent demographics, autopsy and toxicology re-
sults, and life circumstances abstracted from medical examiner
and hospital records, death certificates and police reports. These
reports are routinely collected under the jurisdiction of the RI
Office of State Medical Examiners. Cases are identified by re-
view of deaths entered daily in the Medical Examiner Log.
RIVDRS staff abstract and enter data into NVDRS database
software according to CDC procedures and protocols. Data col-
lection for most cases is complete within six months of the death.
Analysis was conducted using SPSS version 14.0.  Rates of
deaths per 100,000 population were calculated using popula-
tion estimates for Rhode Island as of July 1, 2008, from the US
Bureau of the Census.4
RESULTS
Two hundred fifty-eight suicide deaths occurred in Rhode
Island between January 1, 2004 and December 31, 2006.
Suicide deaths were highest among men, whites and individu-
als age 50-59, as were rates (not shown).  (Figure 1)
Circumstances were known for 255 of 258 decedents
(98.8%).  Where known, the most frequent circumstances re-
ported were associated with mental health: 62.7% of decedents
were reported to be experiencing current mental health prob-
lems with 51.8% reported to be receiving current mental health
treatment. While 48% of males and females were reportedly
depressed, 40.6% of males were reported to have a diagnosis
of depression compared with 51.7% of females. (Table 1) The
most frequent life circumstances reported were: a crisis within
two weeks prior to the suicide (33.3%), an intimate partner
problem (30.2%), and an alcohol or substance abuse problem
(29.4%). The proportion of males
reported to be experiencing these
problems was higher than the pro-
portion of females.
Differences in suicide circum-
stances by age of decedent were also
observed.  (Table 2) While close to
50% of decedents across age groups
were reported to be in a depressed
mood, a smaller proportion of vic-
tims age 13-34 than older victims
were reported to have had a current
mental health problem and to have
a diagnosis of depression.  A higher
proportion of victims age 13 to 34
years had experienced a recent crisis
while a higher proportion of victims
age 65 years and older were reported
to have had a physical health prob-
lem.  Higher proportions of younger
decedents (<65 years) were reported
to have had intimate partner prob-
lems and alcohol or substance abuse
problems.
Figure 1:  Percentage Distribution of Suicides by Age, Race/Ethnicity and Gender,
Rhode Island 2004-2006.
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DISCUSSION
 RIVDRS data reveal important age and sex differences
that can inform prevention efforts.  Nationally, the highest rates
of suicide are observed among older individuals although rates
in middle-age males have been increasing since 1999.2,5 In
contrast, in RI the highest rate of suicide was observed for in-
dividuals age 50-59; therefore, prevention efforts in RI should
target this population.  RIVDRS circumstance data indicate
that mental health problems may be under-recognized and
under-treated, particularly among males and persons less than
age 35.  In addition persons experiencing life crises, intimate
partner problems, and substance abuse problems, particularly
males and younger individuals, appear to be at increased risk
of suicide while older individuals with physical health prob-
lems also appear to be at increased risk.
Knowledge of suicide circumstances provides new informa-
tion on at-risk individuals and can inform the development of
more targeted prevention interventions. While middle-age males
appear to be at particularly increased risk, this population may
be difficult to reach.  Physicians can assist in this effort by using
patient visits for episodic and routine care to identify and refer
patients potentially at-risk for assessment and treatment.
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In January 2008, a case of active infectious tuberculosis (TB)
was reported to the Center for Epidemiology and Infectious
Diseases at the Rhode Island Department of Health
(HEALTH). Control measures put in place included home
quarantine and treatment of the index case (using daily ob-
served therapy) and extensive evaluation of all persons exposed
to the index case in school and non-school settings. The inves-
tigation revealed a secondary case of active infectious TB in the
school linked conclusively to the index case. No other active
cases were documented as part of this outbreak.
TB is a bacterial infection of the lungs, which is transmitted
through the air-borne route from infectious droplets expelled from
the lungs during coughing, sneezing etc. The standard method for
detecting TB infection is by performing a tuberculin skin test (TST),
by injecting a small amount of “Purified Protein Derivative” (PPD)
into the forearm, and observing the reaction. The test needs to be
repeated 8-10 weeks after the baseline test, as “conversion” (an indi-
cator of development of immunity after infection) is a slow process.
TB develops after acquiring infection in two forms, active TB (which
can be infectious and symptomatic), and much more commonly, a
latent form (called latent TB infection or LTBI) where the germs
are contained in the body in a dormant or “latent” capacity and the
person feels well; individuals with latent TB infection are not infec-
tious; the only indication of infection usually is a positive TST. LTBI
has the potential of becoming active (10% overall lifetime risk),  so
should be treated as well.  Both forms of TB can be treated with
regimens of anti-tuberculosis antibiotics.1
CASES AND CONTACT INVESTIGATION
The index patient, a 17 year old 11th grader, was symptom-
atic with cough, fever, and a 10 pound weight loss during the 10
weeks preceding diagnosis, and continued to attend school and
work at an after school job while infectious. A chest radiograph,
TST, and sputum examination all confirmed infectious active TB.
Thus the risk of exposure among immediate family members, close
Tuberculosis Outbreak In a Rhode Island High School
John P. Fulton, PhD, Utpala Bandy, MD, MPH, Michael Gosciminski, MT, MPH,
Carol Browning, MS, RN, BC, Christine Goulette, MS
DAVID GIFFORD, MD, MPH, DIRECTOR OF HEALTH
RHODE ISLAND DEPARTMENT OF HEALTH EDITED BY JOHN P. FULTON, PHD
friends, and co-workers was considered high. The risk of exposure
to classmates, other student contacts, and staff at the high school
was also high. The patient was placed on treatment for active TB
and quarantined at home until non-infectious. An immediate con-
tact investigation and intense case finding process was undertaken,
in accordance with CDC guidelines.2
HEALTH immediately initiated skin testing for TB among
all close community and household contacts identified in the course
of the ongoing investigation. Additionally, skin testing was initi-
ated at the high school with a recommendation that all classmates
of the patient, all additional students in grades 11 and 12, and all
staff be tested. HEALTH tested all eligibles twice, once in January,
to establish baseline reactions to the test, and again in March, to
identify possible “conversions” from negative to positive skin test
results, as an indicator of newly acquired infection.  As expected,
several students and members of the school staff either gave a his-
tory of positivity to previous TB tests or tested positive at baseline,
in January 2008. All such individuals who had not been diag-
nosed and treated previously for LTBI received referral to the state-
supported RISE TB Specialty Clinic affiliated with the Miriam
Hospital in Providence for full medical evaluation and treatment.
In March a second round of testing was conducted. Several
skin test conversions were identified among students and staff, and
these individuals were referred to the TB Clinic for medical work-
up and treatment. All conversions except one student, an 11th
grade female, were diagnosed with LTBI. The 11th grader was
diagnosed with active, infectious TB on the basis of positive chest
radiograph and positive sputum results. The student was placed
on a medication regimen for active TB and was quarantined at
home until non-infectious. Subsequent investigation revealed a
close social connection between the first and second infectious
patients. Additional genotyping results showed a spoligotype and
MIRU (mycobacterial interspersed repetitive units) result that
matched the index patient’s isolate but no other isolate recorded
in the National TB Genotyping Service (NTGS) database of over
35,000 isolates, thus confirming that the first patient was the most
probable source of infection for the second.
Because the second infectious 11th grader may also have ex-
posed others at the high school, HEALTH conducted a third round
of testing in June (8-10 weeks after last exposure to the second case),
this time inviting students in all grades and all staff in the school to
receive TSTs. At this time, additional individuals not previously
screened were identified as having histories of positive TSTs for TB
(prior positives). Others tested positive for the first time in June.
Several of the latter were considered “conversions” from previous
negative test results in January, in March, or both; the rest were
considered “baseline positives.” All such individuals were referred
to the RISE TB Clinic for medical work-up and treatment. None
were found to be infectious, i.e., none were found to have active TB.
Table 1 - Frequencies
Testing Category Students Staff Total
Prior Positives 66 3 69
Baseline Positives 40 6 46
Conversions 18 2 20
(Attributable to Case 1 or 2)
Conversions 7 0 7
(Attributable to Case 2)
Negatives 616 100 716
Partially Evaluated 59 28 87
Not Evaluated 145 8 153
Total 951 147 1098
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RESULTS OF CONTACT INVESTIGATION: STUDENTS
In the course of three rounds of TB testing, HEALTH at-
tempted to evaluate 951 students. HEALTH was unable to test
145 in any of the three rounds, because of absenteeism, suspension
from school, or election not to be tested. Another 59 were tested in
rounds one or two but not in round three. (Table 1). Given possible
exposure to the second infectious patient, students not evaluated in
round three are considered not to be fully evaluated. HEALTH
and school officials have made every attempt to reach these students
thus far, and continue active surveillance with the goal of full evalu-
ation of all students potentially exposed to active infectious TB. (Nei-
ther the state nor the CDC recommends that asymptomatic indi-
viduals—students or staff members—be excluded from school.)
616 students tested negative in the third round of testing,
and were therefore considered negative for TB (negative for
LTBI and negative for infectious TB). In all, 131 of the 806
students tested at least once had positive test results. Of these
students, 66 reported prior positive skin tests (prior positives),
and 40 had positive test results when first tested at the high
school (baseline positives). Baseline testing of students occurred
in round one (January) as well as round three (June).
25 students tested negative in one round of testing (rounds
one or two), then positive in a subsequent round of testing (rounds
two or three), and therefore were considered conversions. Given
the timing of testing (and because the infectious periods of the
two cases overlapped), 18 of the 25 students may have converted
because of exposure either to the first and/or to the second infec-
tious case. Another seven may have converted because of expo-
sure to the second infectious case, but not to the first. These stu-
dents were recorded negative 8-10 weeks after exposure to the
first case, but converted subsequently. Given two infectious cases
in a densely populated congregate setting, it is likely that most of
the recorded conversions were related to recent exposure, but a
small, undetermined number of conversions may also be explained
in one of two ways: a) recent exposure to another infectious case
outside the high school, (for example while visiting in a highly
endemic country for more than 4 weeks—a few “converters” gave
such a history); or b) LTBI acquired in early childhood, where the
skin test intensity wanes to become negative on initial testing, but
subsequent, positive reactions are stimulated by the first test -  phe-
nomenon called “boosting.”
The numbers of prior positives, baseline positives, and
conversions may be reduced to rates by carefully constructing
denominators from the number of students who were tested
successfully in different rounds.  (Table 2).
• Background positivity: 13% of students tested positive,
either prior to testing at the high school or upon first
being tested at the high school.
• Conversions linked to cases 1 or 2: 3% of students con-
verted in the second or third round of testing, after test-
ing negative in the first round. These conversions may be
attributed to either of the two infectious cases.
• Conversions linked to case 2 alone: 1% of students con-
verted in the third round of testing, after testing negative
on the second round. These conversions may be attrib-
uted to the second infectious case (but not to the first
infectious case).
RESULTS OF CONTACT INVESTIGATION: STAFF
In the course of three rounds of TB skin testing, HEALTH
attempted to test 147 staff members, including faculty, adminis-
trative staff, cafeteria staff, and custodial staff. HEALTH was
unable to test a total of eight in any of the three rounds, because
of election not to be tested. Another 36 staff members were tested
in rounds one or two but not in round three (See Table 1). Given
possible exposure to the second infectious patient, staff mem-
bers not evaluated in round three are considered not to be fully
evaluated. To date, HEALTH and school officials have made
every attempt to convince staff members to be fully evaluated,
and continue to do so with the goal of full evaluation of all staff
members potentially exposed to active infectious TB.
100 of the staff tested negative on the third round of test-
ing, and were thus considered negative for TB (negative for LTBI
and negative for infectious TB). In all, 11 of 139 staff members
tested at least once had positive test results. Of these, three re-
ported prior positive TSTs (“prior positives”), and six tested posi-
tive on first testing at the high school (“baseline positives”). Baseline
testing of staff members occurred in round one (January) as well
as round three (June). Two staff members tested negative in one
round of testing, then positive in a subsequent testing, and there-
fore are considered “conversions.” Because of the timing of the
tests, the two conversions among staff members may be attribut-
able either to the first or to the second infectious case.
The numbers of prior positives, baseline positives, and
conversions may be reduced to rates by carefully constructing
denominators from the number of staff members who were
tested successfully in different rounds (Table 2).
• Background positivity: 6% of staff members tested posi-
tive either prior to testing at the high school or upon first
being tested at the high school.
• Conversions attributed to cases 1 and/or 2: 2% of staff
members converted in the second or third rounds of test-
ing, after testing negative in the first round. These conver-
sions may be attributed to either of the two infectious cases.
• Conversions attributed to case 2 alone: None.
MEDICAL REFERRAL AND CASE MANAGEMENT
All persons evaluated with a positive TB skin test on any of the
three rounds of testing (including prior positives, baseline positives,
and conversions) were referred to the state-supported Rise TB Spe-
cialty Clinic affiliated with the Miriam Hospital for follow-up evalu-
ation, diagnosis, and treatment. Typically, a patient thus referred is
Table 2 - Rates
Testing Category Rate
Students
Background Positivity:         (66+40)/ 806 13%
Conversions (Case 1&/or 2): (18)/ 679 3%
Conversions (Case 2):                 (7)/ 623 1%
Staff
Background Positivity:       (3+6)/139 6%
Conversions (Case 1&/or 2) (2)/108 2%
Conversions (Case 2):    (0)/100 0%
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questioned carefully to develop a comprehensive family, social, and
illness history. After full medical evaluation and diagnosis, patients
are prescribed medication regimens for their LTBI or active disease.
Patients are followed closely throughout this period to assure strict
adherence with therapy and completion of therapy. As the period
of therapy is several months, regular follow-up medical care and
counseling is important in TB case management. Less-than-strict
adherence to drug regimens can result in the development of drug-
resistant organisms which are very difficult to cure and increase the
risk of prolonged infection and death, both for active disease and
LTBI, should reactivation occur.
LESSONS LEARNED AND RECOMMENDATIONS
1. Mass Clinic Operations: Schools are good settings for mass
clinic operations in a public health emergency. HEALTH acti-
vated ICS (Incident Command System), which organized the
effort and provided resources far beyond those immediately avail-
able from the small TB program at HEALTH. The ICS structure
thus fielded included a large operations unit (with branches ad-
dressing several areas such as epidemiology, school testing clinic,
laboratory etc.), assisted by legal, financial, logistics, planning, safety,
and communications units. The three mass TB skin testing clinics
at the school ran efficiently, staffed by a team of professionals from
HEALTH, the high school, the RISE TB clinic, and Rhode Island’s
Disaster Medical Assistance Team (RI DMAT). Clinic team
members, led by a TB program nurse, worked closely with one
another to effect rapid and efficient processing of students and
faculty.  As well, a Public Health Advisor assigned by request from
the Division of TB Elimination at the Centers for Disease Control
and Prevention (CDC) provided valuable assistance with the third
(final) testing round at the high school, tracking down difficult-
to-find high risk contacts in the community, as well as providing
guidance and assistance with the in-school screening itself. The
smoothness of the operation engendered confidence in students
and staff members, and undoubtedly among parents as well, who
were kept regularly updated through meetings at the school about
the progress of screenings in the aggregate, and about the specific
test results of their children (by letter), as the latter became avail-
able. Staff members of the high school were also updated in sepa-
rate assemblies so that they could provide appropriate public health
messages to students and parents, while allaying their own fears.
2. TB Clinical and Laboratory Resources: The mass testing
resulted in the referral of 142 students and staff members to the
state-supported TB Clinic for follow-up evaluation, diagnosis, and
treatment as necessary. The availability of this specialized resource
was directly responsible for the rapid and accurate identification
of the second case, leading to early treatment and early quarantine
as a control measure, thus preventing an escalation of transmis-
sion. The TB Program has a long-standing contractual relation-
ship and a strongly collaborative work relationship with the Miriam
Hospital and its state-funded TB Clinic. Maintenance and sup-
port of an expert facility to assure response capacity for TB control
in routine and outbreak situations such as this one is a critical core
function of state government. In the absence of this clinic the con-
trol response would have been difficult, and cases of TB may have
gone undetected.  The clinic is supported by the state
mycobacteriology laboratory that houses modern technology ca-
pacity for TB laboratory testing, and is a critical arm of TB control
as well. The state laboratory serves all clinicians in the state.
3. LTBI prevalence: Data were studied to provide prevalence
rates for LTBI by country of origin in this school population. Of
note, prior history of a documented TB positive skin test was nine
times more common among students born outside the US (18.1%)
than those born in the US (2.1%). These numbers are not very
different from national estimates of LTBI prevalence among US
born and foreign born persons as determined by the National Health
and Nutrition Examination Survey (NHANES) 1999-2000.4
HEALTH now has an excellent cross-sectional view of LTBI preva-
lence among high school students in one of its most diverse munici-
palities. The school population is 60% Hispanic, 10% non-His-
panic Black, 16% non-Hispanic white, and 7% Portuguese or Cape
Verdean. The baseline and prior LTBI cases hailed from many coun-
tries including Guatemala, The Dominican Republic, Colombia,
Cape Verde, Mexico, Liberia, and Poland, to name a few. The most
important risk factor associated with LTBI is foreign nativity.
The data clearly support American Academy of Pediatrics
practice guidelines to perform targeted testing (not universal
screening) for TB during prescribed periodic well child visits,
especially among the foreign born who are immigrants from
countries with high TB disease rates or who travel to such coun-
tries for more than four-week stays. Pediatricians are encour-
aged to perform testing and to ensure completion of LTBI treat-
ment for such children. Universal TB skin testing outside the
setting of a medical home is not recommended.3,5 A commit-
ment to test is generally considered a commitment to treat.
4. TB Control Priorities and Direction: The control and
elimination of TB relies on two critical concepts: a) Successful treat-
ment of all infectious cases, and b) prevention of active TB disease
by treating LTBI, identified through contact investigations and
targeted testing.1 Mass testing at the school uncovered 24 cases of
LTBI (and one active case) related to recent contact with an active
case. These are the highest priority contacts for ensuring treat-
ment adherence and completion. They are at highest risk (in the
first two years following infection) of progressing to active TB. The
139 individuals who have prior or baseline LTBI (most represent
individuals who are candidates for targeted testing based on country
of origin) are also priority candidates for LTBI therapy, as adoles-
cence is a prime age group in which LTBI can progress to active
TB. Thus, this entire group is a priority group for assuring comple-
tion of therapy. Staff of the TB Program at HEALTH, school nurses,
and staff of the RISE TB Clinic will continue to track these prior-
ity groups to assure completion of therapy in the months to come.
This outbreak has burdened all available resources of the small RI
TB Program and the RISE TB clinic with a large bolus of patients;
therefore, continued support for this public health assurance func-
tion of state government is imperative.
Primary care clinical providers must also develop expertise
in the performance of targeted testing for LTBI and in the treat-
ment of cases so detected, because the ongoing detection and
treatment of LTBI is essential to the prevention of progression to
active TB.  See  http://www.health.ri.gov/disease/communicable/
tb/ltbi-resources.php for clinical guidance on treatment of LTBI.
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Additionally, LTBI surveillance will be made operational as part
of our TB Control strategy in RI beginning in 2009, following
proposed revisions to the rules and regulations for the reporting
of communicable diseases. Clinical providers will receive guid-
ance on LTBI reporting in the next few months.  Trend data on
LTBI prevalence, demographics, treatment adherence, and bar-
riers to care will inform future public health policies with regard
to community-based LTBI clinical care.
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Pyogenic Ventriculitis
Antonio Alvarez, MD, and Glenn Tung, MD, FACR
Images In Medicine
An unresponsive 52 year-old woman was brought to the emergency department.
Noncontrast CT of the brain (Figure 1) showed a left frontal mass (arrow) with
edema. After open drainage of the pyogenic brain abscess, antimicrobial therapy
was begun. MR imaging was performed because of neurologic deterioration. A con-
trast-enhanced T1-weighted image (Figure 2) shows a small residual rim-enhancing
frontal brain abscess (arrow) and linear enhancement of the ependyma in the fron-
tal (notched arrow) and occipital horns (bent arrow) of the left lateral ventricle. A
diffusion-weighted MR image (Figure 3) demonstrates hyperintense signal in both
the core of the brain abscess (arrow) and in dependent ventricular fluid (bent ar-
row). Purulent fluid was drained from a ventricular shunt catheter, confirming the
diagnosis of pyogenic ventriculitis.
Pyogenic ventriculitis is a rare and potentially lethal cerebral infection that
can result from rupture of a brain abscess, extension of meningitis into the ven-
tricles, or a complication of neurosurgery.1,2 Signs of ventricular empyema on MR
imaging include hydrocephalus, abnormal signal in the periventricular white mat-
ter, ventricular debris, and ependymal contrast-enhancement.1 Purulent fluid within
the ventricles or in the core of a pyogenic abscess should be suspected when water
diffusion is markedly decreased on diffusion-weighted MR imaging, a sign attrib-
uted to the high viscosity or presence of inflammatory cells and proteinaceous
debris in pus.1
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Physician’s Lexicon
Number (a)
194
158
28
44
28
Number (a) Rates (b) YPLL (c)
2,724 254.6 3,894.0
2,251 210.4 5,730.0
393 36.7 614.5
546 51.0 8,693.0
418 39.1 295.0
Reporting Period
12 Months Ending with September 2007
September
2007
Underlying
Cause of Death
Live Births
Deaths
Infant Deaths
Neonatal Deaths
Marriages
Divorces
Induced Terminations
Spontaneous Fetal Deaths
Under 20 weeks gestation
20+ weeks gestation
Number Number Rates
1,118 13,163 12.3*
988 10,090 9.5*
(5) (97) 7.4#
(5) (74) 5.6#
253 6,729 6.3*
278 3,062 2.9*
398 4,978 378.2#
45 851 64.7#
(40) (774) 58.8#
(5) (77) 5.8#
Reporting Period
12 Months Ending with
March 2008
March
2008
Vital Events
Rhode Island Monthly
Vital Statistics Report
Provisional Occurrence
Data from the
Division of Vital Records
(a) Cause of death statistics were derived from
the underlying cause of death reported by
physicians on death certificates.
(b) Rates per 100,000 estimated population of
1,067,610
(c) Years of Potential Life Lost (YPLL)
Note: Totals represent vital events which occurred in Rhode
Island for the reporting periods listed above. Monthly pro-
visional totals should be analyzed with caution because the
numbers may be small and subject to seasonal variation.
* Rates per 1,000 estimated population
# Rates per 1,000 live births
RHODE ISLAND DEPARTMENT OF HEALTH
DAVID GIFFORD, MD, MPH
DIRECTOR OF HEALTH EDITED BY COLLEEN FONTANA, STATE REGISTRAR
VITAL STATISTICS
Diseases of the Heart
Malignant Neoplasms
Cerebrovascular Diseases
Injuries (Accidents/Suicide/Homicde)
COPD
The medical vocabulary of the urinary
system, a one-way fluid-conveying entity
from renal pelvis to urethra,  employs
words of both Greco-Roman and Ger-
manic origins, and even ventures hesi-
tantly into early Greek mythology.
The word, kidney, is derived from
an older Germanic word meaning egg-
like, presumably chosen because of the
oval shape of the organ. The Classical
adjectival words, renal and nephric, are
derived, respectively, from the Latin, ren,
and the Greek, nephros.
The word, bladder, comes from an
Old English word, blaedre, meaning blis-
ter or sac; and this word, in turn, derives
from an older Teutonic word meaning
to inflate. The word, cyst [as in cystic, cys-
titis, cystoscopy] is Greek, meaning a
pouch or sac and descends from an ear-
lier Indo-European word meaning to
expel or sigh.
Cloaca is from the Latin, clovaca,
meaning a sewer [and specifically, Rome’s
major sewer draining into the Tiber river.]
The word stems from a Greek word
meaning to rinse or drench and is cog-
nate with the Greek root, clys - , seen in
medical terms such as clyster [a syringe],
or clysma [an enema]. The English word,
cataclysm [a violent upheaval, a washing
out] contains the same root.
Urine, and related words [ureter,
urethra] are derived from the Greek, our,
meaning urine.
The word, sphincter, the muscles con-
trolling egress from the bladder, comes from
a Greek word meaning that which strangles
or grips. In Greek mythology, a winged
monster with a woman’s head, a lion’s body,
a serpent’s tail and the wings of an eagle,
stood astride the ancient road to Thebes
and was called Sphinx [derived from the
same Greek root]. The Sphinx confronted
Pilgrims on this road and gave them a
riddle. If the answer was incorrect, the
Sphinx strangled and ate the hapless jour-
neyman. Oedipus, in Greek legends, an-
swered the riddle correctly; and the Sphinx,
in frustration, cast herself over a cliff and
perished.  The family of complex chemi-
cals called the sphingolipids [and deriva-
tive words such as sphingolipidosis, sphin-
gosine, sphingomyelin] come from the
same Greek root, but they were chosen not
to signify strangling, but as a metaphor for
mysteriousness or enigmatic, terms often
used to describe the Thebes Sphinx.
– STANLEY M. ARONSON, MD
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NINETY YEARS AGO, SEPTEMBER 1918
C. Augustus Simpson, MD, in “Nodular Syphilis,” de-
scribed two patients, “each wrongly diagnosed with epithe-
lioma.” He cautioned: “A history of syphilis is seldom obtained,
the patient purposely or carelessly forgetting the incidents.”
In “Recent Progress in the Study of Certain Infections,”
Alex. M. Burgess, MD, advised: “As a result of the war the
investigation of several of the infectious diseases has received a
very strong stimulus. The need for more effective control of
some of these, especially … pneumonia and epidemic menin-
gitis, has become so urgent a matter that many of the best
trained investigators in the fields of bacteriology and sanitation
have been devoting their entire time to the subject.”
In “State Hospital for Mental Diseases,” Arthur H.
Harrington, MD, noted that before 1870, “the insane charge-
able to the State of Rhode Island and to various cities and
towns…were cared for at Butler Hospital, in hospitals and asy-
lums in other states, in various almshouses within the State,
and in some cases patients were entrusted to the care of per-
sons who would agree to provide for them at the lowest price.”
After 1879, the state linked the care of the “insane” “to that of
the poor, reformatory, and correctional classes.”  “Even today
the line of cleavage between the mentally sick with other classes
is somewhat obscured because the unfortunates afflicted with
mental disease, the maimed in body, minor offenders against
the law as well as criminals of all grades…are all located at
Howard.”  In 1918 the capacity of the hospital “without crowd-
ing” was 1385 patients, costing $900,000.
FIFTY YEARS AGO, SEPTEMBER 1958
Congressman John E. Fogarty contributed “Medical Re-
search in the Prevention and Treatment of Tuberculosis” [an
address given before the National Tuberculosis Association Con-
vention, Philadelphia].
In “New Regulations Imposed for Civilian Medicare Pro-
gram,” the Department of Defense listed new rules, following
Congressional action on Medicare appropriations.
An Editorial, “The National Foundation,” discussed the
transition of the National Foundation for Infantile Paralysis
[devoted to polio research] to the National Foundation.
TWENTY-FIVE YEARS AGO, SEPTEMBER 1983
An Editorial, “The Specter of Alzheimer’s Disease,” by
Stanley M. Aronson, MD, cited statistics: 1% for people ages
65-74, 4% for ages 75-84, 10% for ages 85 and older.
Ralph Barlow, pastor, Beneficent Congregational Church,
Providence, in “Senile Dementia: Metaphor for Our Time,”
explained that his father had “sunk” into senile dementia over
10 years. The condition was successively diagnosed as “arterio-
sclerosis, organic brain syndrome, and finally, Alzheimer’s Dis-
ease.” He spent his last 3years in a nursing home, where his
relationships with others deteriorated, echoing many relation-
ships in American society.
James R. McCartney, MD, and Linda Palmateer, RN, MS,
in “Dementia and Delirium: Detection in the General Hospi-
tal,” urged clinicians to give a “high priority” to the detection
and management of dementia and delirium.
A. Hunter Dupree, PhD, George Littlefield Professor of
History Emeritus, Brown, had cared for a demented relative
for 20 years. Professor Dupree contributed “A Strategy for Those
in the Shadow of Alzheimer’s Disease,” He urged “Govern-
ment and the health professions [to] support efforts to solve
the biological, social and human problems.”
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